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Papain-like cysteine proteases bear an enormous potential as drug discovery targets for
both infectious and systemic human diseases. The considerable progress in this field
over the last two decades has also raised interest in the visualization of these enzymes
in their native context, especially with regard to tumor imaging. After a short introduction
to structure and general functions of human cysteine cathepsins, we highlight their
importance for drug discovery and development and provide a critical update on the
current state of knowledge toward their involvement in tumor progression, with a special
emphasis on their role in therapy response. In accordance with a radiopharmaceutical
point of view, the main focus of this review article will be the discussion of recently
developed fluorescence and radiotracer-based imaging agents together with related
molecular probes.
Keywords: cancer, carcinogenesis, extracellular enzymes, fluorescence-based probes, lysosomal cysteine
proteases, metastasis, molecular imaging, radiotracers
Introduction: Structural and Biochemical Considerations
The term cathepsins was introduced by the famous chemist Richard Willstätter (1872–1942)
and his PhD student Eugen Bamann (1900–1981) for the entirety of the intracellular proteases
referring to their protein-degrading activity (greek καθεψειν = to digest, to boil) in the first half
of the last century (Figure 1) (Willstätter and Bamann, 1929). In this sense, their physiological
functions were for long time considered to be restricted to cellular protein catabolism. The
class of proteases referred to as cathepsins represents a structurally heterogeneous group of
enzymes. However, in humans the majority of them belong to the mechanistic class of the
cysteine proteases as they contain a highly conserved cysteine residue in their active sites. Because
they share a high degree of homology to the plant enzyme papain, the cysteine cathepsins
are included in the C1 family of clan CA according to the MEROPS protease classification
system (Rawlings et al., 2014)1. In addition to the 11 papain-like cathepsins B, C, F, H, K,
L, O, S, V, W, and X, four non-cysteine cathepsins are present in humans, i.e., the serine
proteases cathepsins A (also referred to as serine carboxypeptidase A) and G and the aspartic
proteases cathepsins D and E (Kirschke, 2008). With the exception of cathepsin C, which is
present as a homotetramer, all cysteine cathepsins are monomeric single domain enzymes with
1http://merops.sanger.ac.uk/cgi-bin/clansum?clan=CA.
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FIGURE 1 | Richard Willstätter (left) and Eugen Bamann (right), the coiners of term cathepsin. © Archive of Deutsche Akademie der Naturforscher
Leopoldina, M1 3416 and M1 4898.
molar masses ranging between 24 and 28 kDa for the mature
enzymes. As characteristic for all papain-like enzymes, their
structure is composed of two subdomains referred to as the
L (left)- and the R (right)-domains. The N-terminal L-domain
is dominated by α-helical structures among which a long N-
terminal α-helix that harbors the active-site cysteine residue
at its beginning is the most striking element. The R-domain
is located toward the C-terminus and is characterized by a β-
barrel motif. The V-shaped active-site cleft is situated between
the two subdomains with the residues cysteine 25, histidine
159, asparagine 175, and glutamine 19 (papain numbering)
constituting the catalytic center. The binding sites that recognize
the amino acid side chains on the peptidic substrates are located
in alternating sequence on the L- and R-subdomains which
requires the substrate to be present in the extended conformation
for productive binding (McGrath, 1999; Brömme, 2001; Grzonka
et al., 2001; Turk et al., 2001b, 2003, 2012; Lecaille et al., 2002;
Stoka et al., 2005). Figure 2 explains the structure of papain-like
cysteine proteases exemplarily for human cathepsin B.Within the
S2 to S1
′
binding sites (see Figure 3 for explanation) the contacts
to the substrate comprise non-covalent interactions to the side-
chain entities and hydrogen bonds to the peptidic backbone.
The enzyme-substrate contacts beyond these sites, i.e., S3 and S2
′
in the N- and C-terminal direction, respectively, are devoid of
hydrogen bonds and less well-defined (Turk et al., 1997; Turk and
Guncˇar, 2003). Regarding the mechanism of catalysis, instructive
insights have been gained from investigations on papain, which
in principle can be translated to the other members of the clan
CA proteases including the cysteine cathepsins. A catalytic triad
is formed by cysteine 25, histidine 159, and asparagine 175.
Due to the formation of a thiolate-imidazolium ion pair, the
active-site cysteine is present as a permanent negatively charged
nucleophile. The ion pair is stabilized by the asparagine 175
whose side chain carbonyl oxygen acts as an H-bond acceptor
toward the imidazole NH of histidine 159, which results in an
increased basicity of this imidazole moiety (Vernet et al., 1995).
Further, stabilization of the thiolate arises by the fact that the
active-site cysteine is located at the beginning of the N-terminal
α-helix mentioned before, which enables the negative charge to
be stabilized by the helix macrodipole (Rullmann et al., 1989).
In addition, the thiolate-imidazolium ion pair is shielded from
solvent by the side chain of tryptophan 177 (Gul et al., 2008).
The stabilized negative charge renders the active-site cysteine
capable of nucleophilic attack toward the peptide bond in the
substrate resulting in the formation of a transient thiol ester.
During this step, a tetrahedral intermediate is passed, whose
oxygen-centered negative charge is stabilized by H-bond contacts
to one of the side chain amide proton of glutamine 19 and the
backbone NH of cysteine 25, the so called oxyanion hole. Upon
collapse of this tetrahedral intermediate, a proton is transferred
from the imidazolium moiety of histidine 159 to the nitrogen
of the cleaved peptide bond which results in the release of the
C-terminal cleavage product from the enzyme. In the following
step, the neutral imidazole ring of the histidine acts as general
base upon nucleophilic attack of the thiol ester by water under
the formation of a second tetrahedral intermediate. The collapse
of this intermediate releases the N-terminal cleavage product and
restores the thiolate-imidazolium ion pair ready for another cycle
of catalysis.
The majority of the human cysteine cathepsins act as
endopeptidases. Exopeptidase activity is exhibited by the
cathepsins B, C, H, and X. Several structural characteristics
determine their action as endopeptidases (Turk and Guncˇar,
2003; Novinec and Lenarcˇicˇ, 2013b). For example, in the case
of cathepsin B two histidines are located in an insertion that
comprises 20 amino acids in the L subdomain referred to as
occluding loop. These two residues engage the C-terminus of
the peptidic substrate in hydrogen bond/salt bridge contacts,
which results in carboxydipeptidase activity by blocking the
access of the substrate beyond the S2
′
binding sites (Figure 2).
Owing to the flexibility of the occluding loop and the variable
protonation state of the histidine side chains, cathepsin B can
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FIGURE 2 | Crystal structures of human cathepsin B. (A) View from
“front,” (B) view from “top”; the occluding loop is highlighted in yellow,
residues Cys29, His199, Gln 23, and Trp221 correspond to Cys25, His159,
Gln19 and Trp177 in papain, respectively, (C,D) cathepsin B (shown in gray
surface) in complex with CA074 (9a, shown in sticks). Pictures were
prepared with PyMOL (DeLano, W. L. The PyMOL Molecular Graphics
System. Version 1.5.0.3 Schrödinger, LLC) using the PDB file 1QDQ (2.2 Å)
(Yamamoto et al., 2000).
FIGURE 3 | Annotation of binding sites and amino acid residues for the
description of the protease-substrate interaction.
act both as exo- and endopeptidase. Typically for papain-like
proteases, the endopeptidase specificity of the cysteine cathepsins
is mainly governed by the S2–P2 interactions. Investigations on
oligopeptides have revealed that the substrate specificity strongly
overlaps and differs only subtly between the individual members
(Choe et al., 2006). However, regarding protein substrates,
the specificity seems to be more distinct among the different
cathepsins (Biniossek et al., 2011) and several protein substrates
are selectively cleaved in the presence of other proteins. This
selectivity might arise from the fact that the cathepsins, as the
majority of proteolytic enzymes, recognize their substrates in
an extended conformation that in proteins can only be adopted
within flexible loops (Madala et al., 2010). Furthermore, the
sterical accessibility of the recognition sequences will certainly
determine their substrate properties in addition to the primary
structure and conformational properties. The distinctive action
on protein substrates enables the specialized roles of the
cysteine cathepsins in the molecular wheelwork of crucial cellular
processes. In this regard, it is interesting to point out that many
cathepsins are able to hydrolyze components of the extracellular
matrix, such as various types of collagen, elastin, proteoglycans,
and fibronectin. The particular matrix proteins that are subject
to cysteine cathepsin-mediated proteolysis have been reviewed in
detail recently (Brömme and Wilson, 2011; Fonovicˇ and Turk,
2014a). All cysteine cathepsins are synthesized as preproenzymes.
The short N-terminal presequences direct the translated proteins
into the endoplasmic reticulum, where this sequence is removed
by the action of the signal peptidase. The resulting proenzymes,
also known as zymogenes, are catalytically inactive as the
proregions (propeptides) block the active sites. Notably, isolated
propeptides act as potent inhibitors toward the mature cysteine
cathepsins (Fox et al., 1992; Kreusch et al., 2000). The lengths of
the proregions vary from 36 amino acids in the case of cathepsin
X to 251 amino acids for cathepsin F. The parts of the propeptides
which are directly attached to the N-termini of the mature
enzymes adopt an extended conformation and block the access
to the active sites by binding in reverse orientation compared to
the substrates. The propeptides can be removed autocatalytically
in the acidic environment of the lysosome or catalyzed by
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other proteases. In addition to preventing a premature activation
of the zymogenes, the proregions act as templates for the
folding of the catalytic domains and direct the enzymes into
endosomal-lysosomal cell compartments (Wiederanders et al.,
2003). Besides the propeptide-catalytic domain interaction the
activity of the cysteine cathepsins is strictly regulated by a
variety of endogenous proteinaceous inhibitors. Among them,
the largest group is represented by the proteins of the cystatin
superfamily, which can be subdivided into the actual cystatins
and the stefins as well as the kininogens. The cystatins consist
of 110–120 amino acids, contain two disulfide bridges and are
mainly present outside the cells. In contrast, the stefines are
intracellular proteins of similar size without disulfide bonds,
whereas the kininogens represent blood plasma proteins with
molar masses of 50–120 kDa. In addition to act as cysteine
cathepsin inhibitors, the kininogens are implicated in blood
pressure regulation as they can be converted to kinines upon
limited proteolysis mediated by the kallikrein serine proteases.
The cystatin-like proteins inhibit cysteine cathepsins more or less
unselectively with inhibition constants in the picomolar range
(Turk et al., 2001a). A further group of proteinaceous inhibitors
is represented by the thyropins, which are proteins that exhibit
homology to thyroglobulin I. Interestingly, the p41 fragment of
the MHC II-associated invariant chain has been identified as a
selective inhibitor of cathepsin L (Turk et al., 2001b). Serpins,
proteinaceous inhibitors which inhibit serine proteases by the
formation of covalent complexes, can also act on papain-like
cysteine proteases in a similar manner (Schick et al., 1998).
Details about the proteinaceous cysteine protease inhibitors are
discussed by several review articles, covering both structural
as well as physiological aspects (Otto and Schirmeister, 1997;
Grzonka et al., 2001; Turk et al., 2002; Rzychon et al., 2004).
Physiological regulation/modulation of cysteine
cathepsin activity can furthermore occur in the presence of
glycosaminoglycans (Novinec et al., 2014). The phenomenon
has been studied in detail for the modulation of cathepsin
K’s collagenolytic activity by chondroitin sulfate (Li et al.,
2002). An X-ray crystal structure of the enzyme in complex
with chondroitin-4-sulfate has been solved (Li et al., 2008).
Furthermore, it has been demonstrated that both chondroitin-
4-sulfate and dermatan sulfate bind to cathepsin K with weak
affinity (KD-values 33 and 9.2µM, respectively) resulting in
a decrease of the apparent Km-value for low-molecular-mass
substrates (Novinec et al., 2010). In contrast, the hydrolytic
activity of cathepsin S is weakly inhibited upon interaction with
chondroitin-4-sulfate (Sage et al., 2013). Similar observations
have been made with cathepsin B in the presence of heparin
and heparin sulfate, while the enzyme experiences stabilization
when being complexed with these glycosaminoglycans at slightly
alkaline pH (Almeida et al., 2001).
Inhibitor Design and Importance of
Cysteine Cathepsins as Drug Discovery
Targets
Inhibitors based on small molecules that target papain-
like cysteine proteases have contributed substantially to the
understanding of the catalytic mechanisms, enzyme-substrate
recognition and the biological functions of this class of
proteolytic enzymes. Most of the known low molecular weight
inhibitors of papain-like proteases are containing electrophilic
entities, referred to as warheads, which give rise to irreversible
or reversible covalent interactions with the active-site cysteine.
The field of small-molecule based inhibitors has been surveyed
by several excellent and comprehensive review articles that
appeared in the recent years (Otto and Schirmeister, 1997;
Leung et al., 2000; Lecaille et al., 2002; Powers et al.,
2002; Abbenante and Fairlie, 2005; Frizler et al., 2010).
Therefore, only a brief discussion of those inhibitor classes
that served as lead structures for the design of imaging probes
reviewed in the next section or those which were used as
molecular tools for their biological evaluation will be given
herein (Figure 4). Compound classes that exert inhibition by
irreversible covalent modification of the active-site cysteine
residue are peptide-derived halomethylketones, diazoketones,
acyloxymethylketones, O-acyl hydroxamates, vinyl sulfones
and epoxides, among other inhibitor chemotypes. Irreversible
inhibitors of cysteine proteases have been reviewed in detail by
Powers et al. The following remarks are mainly extracted from
this reference and also kinetic data on the inhibition by some
of the compounds in Figure 4 can be found therein (Powers
et al., 2002). Peptidic chloromethyl ketones have been developed
as inactivators of serine proteases but they are also potent
cysteine protease inhibitors due to S-alkylation of the active-site
cysteine. Their strong intrinsic reactivity results in modification
of other biological thiols such as glutathione, even though in
slower rates than their interaction with the targeted cysteine
proteases. This drawback renders such inhibitors unsuitable for
the application in cell-based and animal experiments. In contrast,
fluoromethyl ketones such as compounds 1a and b are much
less reactive toward thiols, due to the low energy of the carbon-
fluorine bond. Despite their low inherent reactivity they are
potent inactivators of cysteine proteases and show selectivity
over serine proteases. Similarly, diazomethyl ketones can be
considered to be selective for cysteine proteases, even though
inactivation of serine proteases by this inhibitor chemotype has
been reported for some instances. Their reactivity toward thiols
of low molecular weight is negligible and some radiotracers have
been developed on the basis of this inhibitor class (see Section
125I-labeled Compounds). Acyloxymethyl ketones (AOMK’s; see
compound 2 in Figure 4 for example) have been developed
with the intention to create deactivated versions of chloromethyl
ketones. This inhibitor chemotype has been shown to inactivate
cysteine proteases selectively over other classes of proteolytic
enzymes. In addition to the other reactive methyl ketones, they
provide the opportunity of kinetic tuning upon varying the
acyloxy leaving group. However, their potential susceptibility
toward esterase-catalyzed degradation might compromise their
applicability in vivo (Verdoes et al., 2013). Formal isoelectronic
replacement of the methylene group in the latter inhibitor class
leads to O-acyl hydroxamates, as represented by compound
3. This chemotype forms covalent complexes with the active-
site cysteine in analogy to acyloxymethyl ketones. In contrast,
peptide-derived O-acyl hydroxamates are capable to inactivate
serine proteases, even though their mechanism of interaction
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FIGURE 4 | Inhibitors that were used as experimental tools in studies that are referred to in this article.
may differ between these two classes of proteases (Brömme and
Demuth, 1994). Mechanistically related to the aforementioned
inhibitor classes are peptide-derived epoxides, among which
the epoxysuccinyl peptides constitute the most important
subclass. Differently to reactive methyl ketones, no nucleofuge
is leaving the enzyme-inhibitor complex, as the attack of the
active-site thiol results in epoxide opening. Their prototype is
represented by the fungal secondary metabolite E64 (6), which
has been shown to inactivate a broad spectrum of papain-like
cysteine proteases. Replacement of the guanidinobutyl moiety
by hydroxyphenyl and isobutyl led to JPM-565 (7a) and E64c
(8a), respectively, without significant changes in the inhibitory
potential. Replacement of the leucine residue in E64 (6) by
isoleucine, C-terminal extension by proline and amidation of
the carboxylic group results in CA074 (9a; Figure 4), which
inactivates cathepsin B selectively over other cysteine cathepsins.
Notably, epoxysuccinyl peptides can bind to the active site
in the same or inverse orientation compared to the substrate
binding mode. Esterification of the carboxylic groups in JPM-
565, CA074, and E64 with simple alcohols renders these highly
polar molecules membrane permeable (compounds 7b, 8b, and
9b in Figure 4). Despite the actual inhibitors can be released by
the action of cellular esterases, the corresponding “prodrugs” still
bear inhibitory potential but altered selectivity profiles compared
to their “active” progenies, and cysteine cathepsin inactivation
may occur faster than ester hydrolysis (Bogyo et al., 2000).
Therefore, the results of cell-based experiments in which these
esterified epoxysuccinyl peptides are used for pharmacological
inhibition should be interpreted with care in terms of selectivity
toward individual cysteine cathepsins. E64d (8b) has been
demonstrated to be bioavailable upon oral administration. The
spontaneous reactivity of epoxide inhibitors toward thiols has
been shown to be low. A couple of radiotracers have been
developed starting from epoxysuccinyl peptides (see Section 125I-
labeled Compounds). Besides epoxysuccinyl peptides, peptidic
inhibitors with epoxide warheads have been also created by
replacing formally the terminal carboxylic group of N-terminal
cleavage products by an oxirane ring, resulting in N-peptidyl-α-
aminoalkyl epoxides. They interact with the active site by epoxide
opening upon attack of the active-site sulfhydryl group at the
methylene carbon. Concerning the two possible configurations
at the methine carbon, the erythro diastereomers are more active
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than their threo-configured counterparts. In agreement with the
altered electronic situation of the oxirane moiety, N-peptidyl-
α-aminoalkyl epoxides are less potent inactivators of cysteine
proteases compared to epoxysuccinyl derivatives. A tritium-
labeled N-peptidyl-α-aminoalkyl epoxide has been reported
(see Section Radiotracers Based on Fluorine-18, Radiocarbon
Isotopes, and Tritium; and compound [3H]39 in Figure 11)
(Albeck, 2000; Powers et al., 2002). Vinyl sulfones are cysteine-
reactive moieties that give rise to nucleophilic addition instead
of substitution. Their incorporation at the C-terminus of small
peptides can lead to highly potent inactivators of cysteine
proteases such as compounds 4 and 5 with limited inherent
thiol reactivity. Compound 5 has been used as lead structure
for radiotracer design (see Section 125I-labeled Compounds).
Despite vinyl sulfones inactivate cysteine proteases selectively
over serine proteases, the introduction of three leucine residues
into position P1–P3 renders them capable of ether formation with
the active-site threonine residue in proteasomes.
In contrast to vinyl sulfone warheads for which attack by
the active-site thiol is irreversible, addition to some electrophilic
functional groups can be reversible, which allows the enzyme-
inhibitor complex to dissociate. This holds true for peptide-
derived aldehydes and ketones as well as nitriles, which give
rise to the formation of thiohemiacetals (Otto and Schirmeister,
1997; Shokhen et al., 2011) and thioimidates (Frizler et al.,
2010), respectively. Peptide aldehydes such as compounds 10–12
are highly potent inhibitors for cysteine proteases (Lecaille
et al., 2002). They potentially can also inhibit serine proteases
by interactions analogous to cysteine proteases (Ruiz-Gómez
et al., 2009). For example, the naturally occurring aldehyde
antipain (12) potently inhibits serine proteases such as trypsin
and thrombin, in addition to its inhibitory activity toward
a variety of cysteine proteases2. Amino acid and peptide-
derived aldehydes bear furthermore the potential to inhibit
metallopeptidases, because the oxygen atoms of the hydrate
forms can mediate coordinative interactions with the Zn2+
ion in the active site (Sträter and Lipscomb, 1995). In
contrast, cyano groups are less reactive electrophiles, which
is the reason why peptide-derived nitriles can interact quite
selectively with cysteine over serine proteases (Frizler et al.,
2010). Exceptions are known for the serine protease dipeptidyl
peptidase IV, for which dipeptide nitrile inhibitors have been
developed as the antidiabetic drugs vildagliptin and saxagliptin
(Nabeno et al., 2013).
Partly due to the employment of the aforementioned
inhibitors as experimental tools, the perception about the
biological functions of cysteine proteases, especially those of the
cathepsins, has changed dramatically over the last 20 years and
until today the involvement in a plethora of individual cellular
processes has been revealed for almost every individual cathepsin
(Brix et al., 2008; Reiser et al., 2010). An increased activity of the
cysteine cathepsins, which can result from increased expression
or a reduced level of their endogenous protein inhibitors,
has implications in several pathologies (Katunuma, 2011).
Consequently, the cysteine cathepsins became highly attractive
2http://merops.sanger.ac.uk/cgi-bin/smi_summary?mid=J10.011.
targets to develop drugs for the treatment of systemic human
diseases (Turk et al., 2003). These diseases include autoimmune
and allergic disorders (Reiser et al., 2010; Löser, 2011; Perišic
Nanut et al., 2014), cardiovascular diseases, osteoporosis and
cancer. In light of the pivotal role of cathepsin K in the
degradation of osseous collagen, inhibitors directed against this
protease have been developed to treat osteoporosis (Novinec and
Lenarcˇicˇ, 2013a). These efforts will probably lead to the first
cathepsin inhibitor, named odanacatib, that can be launched to
the drugmarket (13; Figure 5). Odanacatib is a dipeptide-derived
nitrile which targets selectively cathepsin K. This compound is
currently in phase III clinical studies for osteoporosis treatment,
e.g., the Long-Term Odanacatib Fracture Trial (LOFT) (Bone
et al., 2015), and in various phase II and III clinical trials targeting
metastatic bone disease in advanced-stage breast and prostate
cancer (Onishi et al., 2010; Sturge et al., 2011)3,4,5. Its discovery
has been summarized in Gauthier et al. (2008). The most salient
structural features of odanacatib are the replacement of the P3
carbonyl oxygen by a trifluoromethyl group, fluorination at Cγ in
the P2 leucine side chain and a cyclopropyl group that integrates
the Cα atom in P1. The advantages of peptide bond replacement
by trifluoroethylamines have been outlined in Bigotti et al. (2009).
Side-chain fluorination intended to block oxidative metabolism
at the methine group and introduction of the cyclopropyl group
stabilizes the P2-P1 amide against metabolic hydrolysis (Gauthier
et al., 2008).
Furthermore, clinical studies associated with targeting
cysteine cathepsins by small organic molecules have been
reported in the context of cathepsin S inhibitors for the treatment
of rheumatoid arthritis, psoriasis and neuropathic pain (Fonovicˇ
and Turk, 2014b). Generally, cathepsin S inhibition has a high
potential to treat autoimmune-related disorders due to its pivotal
role in MHC II-dependent antigen presentation (Gupta et al.,
2008). Dysregulated antigen presentation in keratinocytes has
FIGURE 5 | Odanacatib, probably the first cysteine protease inhibitor
that will enter the drug market.
3A Study to Examine the Effects of an Experimental Drug on WomenWith Breast
Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED), https://
clinicaltrials.gov/ct2/show/NCT00399802.
4A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis
in Women With Breast Cancer (0822-029), https://clinicaltrials.gov/ct2/show/
NCT00692458.
5A Phase III Study to Assess the Safety, Tolerability, and Efficacy of
MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men
With Castration-Resistant Prostate Cancer, http://adisinsight.springer.com/trials/
700034934.
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been linked to the pathogenesis of psoriasis (Schönefuß et al.,
2010). Moreover, cathepsin S has been demonstrated to elicit
pruritus by activating the protease-activated receptors PAR-2
and PAR-4 in cutaneous nerve fibers (Reddy et al., 2010). These
results contribute to the rationale for developing cathepsin S
inhibitors as antipsoriatic agents. Treatment of neuropathic
pain by inhibiting cathepsin S is mainly deduced from the
enzyme’s ability to liberate the CX3C chemokine fractalkine from
a precursor bound to the surface of dorsal horn neurons, which
triggers inflammatory signaling in microglial cells (Clark and
Malcangio, 2012).
Functions of Cysteine Cathepsins in Tumor
Progression and their Influence on Therapy
Response
For neoplastic diseases, accumulating evidence confirms the
crucial role of several cysteine cathepsins in the progression,
invasion and metastasis of solid tumors. They furthermore seem
to be influencing the response of tumor cells to ionizing radiation
and cytostatic agents (Gocheva and Joyce, 2007; Palermo and
Joyce, 2008; Lankelma et al., 2010; Mason and Joyce, 2011;
Reinheckel et al., 2012; Kos et al., 2014). Despite increasing
evidence for pro-tumorigenic functions of cysteine cathepsins,
individual roles for individual members are difficult to define,
which is partly due to the heterogeneous nature of tumor biology.
Generally, the fatality of neoplastic diseases mainly arises due
to the dissemination of primary tumor cells from their initial
location to colonize distant organs. Even though the range of
target tissues varies among different tumor entities, neoplasms of
the same origin often share the organ pattern of metastasis. For
example, breast and lung adenocarcinomas tend to metastasise to
organs such as bone, lung, liver and brain (Nguyen et al., 2009).
For being able to disseminate from their original location, tumor
cells need to acquire an invasive phenotype. Therefore, they have
to undergo a process of de-differentiation called epithelial-to-
mesenchymal transition (EMT). During this process, which is
initiated by certain growth factors, cells undergo a variety of
functional and morphological changes such as impairment of
cell–cell contacts, loss of apical-basolateral polarity, increased
cellular motility and enhanced extracellular proteolysis (Thiery,
2002; Joyce and Pollard, 2009; Box et al., 2010).
Regarding the EMT hallmark of increased extracellular
proteolysis, the cathepsins are considered to be key players in
this process, in addition to the proteolytic activities that are
exhibited by the matrix metalloproteinases, the uPA/plasmin
system and the aspartic proteases cathepsins D and E, and,
furthermore, serine proteases of the kallikrein family (Schmitt
et al., 1992; Borgoño and Diamandis, 2004; Lee et al., 2004; Affara
and Coussens, 2008; Fröhlich, 2010; Sevenich and Joyce, 2014;
Theocharis et al., 2014). Partial degradation of the extracellular
matrix results in its remodeling, which creates niches and trails
for cell migration and uncovers binding epitopes at matrix
proteins that can be recognized by receptors involved in cell–
matrix interactions such as integrins (Friedl and Alexander,
2011). The functional contribution of the cysteine cathepsins to
tumor invasion and metastasis is manifold. While the potential
implication in tumor progression has been proposed for all of the
11 cysteine cathepsins (Mohamed and Sloane, 2006), the most
striking evidence exists for the cathepsins B, L, S, K, and X (Joyce
et al., 2004).
Besides the degradation of matrix proteins, cysteine
cathepsins are capable of shedding cell surface molecules
that are important for cell adhesion such as cadherin E. This
cell surface protein mediates cell-cell contacts by homophilic
interactions and the attenuation of its expression on malignant
cells correlates with a more invasive tumor phenotype. It has
been demonstrated that cadherin E can be specifically cleaved
by the cathepsins B, L and S and thereby removed from the cell
surface by these proteases (Gocheva et al., 2006).
Not only extracellular but also intracellular protein hydrolysis
catalyzed by cathepsins can contribute to tumor progression.
This has been concluded from experiments in which inhibition
of intracellular cathepsins by E64d (8b) reduces the TGFβ-
1 stimulated invasive capacity of the malignant epithelial cell
lines iPL32 and A549. Because cell migration was impeded even
one day after treatment with 8b had been stopped, a direct
inhibition of extracellular proteolysis during the invasion assay
is unlikely to explain this effect. Furthermore, the effect was
accompanied by the accumulation of enlarged lysosomes in these
cells, which indicates lysosomal protein storage upon inhibition
of cysteine cathepsins (Kern et al., 2015). The work by Kern
et al. confirms similar results that have been obtained by exposing
neuroblastoma cells to compound dideiodo-26b (see Figure 10
for structure), a diazoketone which is a potent inactivator of
the cathepsin B and L (Colella et al., 2010; Cartledge et al.,
2013). In line with these results, exposure of tumor-associated
macrophages to acyloxymethyl ketone 2, which is capable of
inactivating the cathepsins S, L and B, causes oxidative stress
and subsequent apoptosis. These effects were attributed to the
influence of 2 on intracellular proteolysis. The impact of 2 on
tumor growth in vivo has been investigated in the syngeneic
murine 4T1 model. Compound 2 was administered in a dose
of 40mg/kg once a day for 3 days. At day 4 the tumors of
the sacrificed mice were investigated for apoptosis markers
by FACS analysis, which revealed increased programmed cell
death throughout the tumor. Accordingly, the tumor size was
significantly reduced compared to the untreated control. Of note,
2 did not affect the growth of 4T1 tumor cells in vitro, which
indicates the importance of tumor-associated macrophages for
cancer growth (Salpeter et al., 2015).
The member of the cysteine cathepsin family that has been
most intensively discussed in the context of cancer is cathepsin B
(Sloane et al., 2005; Gondi and Rao, 2013; Aggarwal and Sloane,
2014; Kos et al., 2014; Lampe and Gondi, 2014). The enzyme
can be located at the surface of invasive tumor cells in areas
such as focal adhesions and invadopodia where it associates
with the peripheral membrane protein annexin A2. It can be
also present in membrane invaginations rich in cholesterol and
sphingolipids called caveolae by forming complexes with the
protein caveolin-1. Membrane association of cathepsin B seems
to support proteolytic processing of extracellular substrates such
as plasminogen and tissue-type plasminogen activator (tPA),
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tenascin C and type I and IV collagens (Werner et al., 2012).
Elevated activity of cathepsin B has been shown to increase the
malignancy of various neoplasia such as breast cancer (Withana
et al., 2012), glioma (Gole et al., 2009), and melanoma (Matarrese
et al., 2010).
The involvement of cathepsin L in tumor progression is
less evident than for cathepsin B but its contribution to the
invasive and metastatic potential of malignant cells such as
oncogenically transformed fibroblasts and melanoma cells has
been demonstrated (Ravanko et al., 2004; Rousselet et al., 2004).
Furthermore, higher levels of cathepsin L in primary malignant
melanomas have been correlated to poor prognosis (Štabuc
et al., 2005). Taken together, these results render this protease a
potential target in anti-tumor therapy (Lankelma et al., 2010).
The functions of cathepsin S in neoplastic progression are
manifold (Chang et al., 2007). Recent results provide evidence
that secretion of this cysteine protease from tumor-associated
macrophages and endothelial cells is important for tumor
angiogenesis, which is in agreement with findings from earlier
studies (Small et al., 2013). Nidogen-1, a constituent of the
basement membrane, has been shown to be subject of limited
proteolysis catalyzed by cathepsin S (Sage et al., 2012). This
finding provides potential evidence that this enzyme might be
actively involved in tumor invasion. Very recently, the function
of cathepsin S in brain metastasis of primary mamma tumors
has been investigated in detail (Sevenich et al., 2014). In this
study, both genetic ablation and pharmacological inhibition of
cathepsin S with a compound of undisclosed structure has been
demonstrated to result in suppression of the metastatic spread
of human MDA-MB-231 breast cancer cells to the brain in a
mouse model. In particular, cathepsin S facilitates blood-brain
barrier passage of tumor cells by specific proteolytic cleavage of
the junctional adhesionmolecule JAM-B. Interestingly, cathepsin
S is contributed by both tumor and stroma cells with higher
expression of tumor-derived cathepsin S in early brainmetastases
compared to late stage while the expression pattern of stromal
cathepsin S was inversed. These results highlight the potential
of this cysteine protease to drive colonization of distant organs
during tumor metastasis.
The tumor-promoting functions of cathepsin K have been
mainly discussed in the context of bone metastasis (Podgorski
et al., 2007). This issue was briefly mentioned in the previous
section. Apart from its well-confirmed involvement in metastatic
bone disease, cathepsin K seems to have a more general role in
tumor progression. For example, immunoreactivity against this
cysteine cathepsin correlates with increased invasive potential of
lung adenocarcinoma (Rapa et al., 2006).
Accumulating evidence indicates that cathepsin X is a
key protease in tumor invasion. Unique among the cysteine
cathepsins, the enzyme exhibits a strict carboxymonopeptidase
and—dipeptidase activity without acting as endopeptidase
(Nägler et al., 1999; Klemencˇicˇ et al., 2000). However, the action
of cathepsin X in tumor invasion seems to bemainly independent
of its catalytic properties. This is attributed to the presence of
an RGD motif in its proregion in a conformation very similar
to cyclic RGD-pentapeptides. This enables procathepsin X to
interact with the integrin subtype αvβ3 (Lechner et al., 2006).
It has been shown that cathepsin X acts as a promoter of T-
lymphocyte migration along ECM-mimicking Matrigel, which is
partly independent of its proteolytic activity due to stimulation
of integrin signaling (Jevnikar et al., 2008). Accordingly, detailed
investigations in a mouse model of pancreatic neuroendocrine
tumors have revealed that cathepsin X expressed by both tumor
cells and tumor-associated macrophages drives malignancy via
integrin signaling without involving its proteolytic activity.
Interestingly, procathepsin X secreted from tumor-associated
macrophages was capable of stimulating the invasive potential of
the cancer cells while their proliferation could only be stimulated
by procathepsin X expressed by the cancer cells themselves.
This phenomenon probably originates from interactions between
procathepsin X and the intracellular domain of the integrin β
chain (Akkari et al., 2014).
The findings mentioned above highlight the manifold
functions of cysteine cathepsins in general tumor development.
In the following subsection we will discuss their role in the
response of tumors to cytostatic therapies.
Considerations on Cysteine Cathepsin Inhibitors
as Adjuvant Radiosensitizers and
Chemosensitizers
The improved methods for prevention and early detection of
cancer, as well as recent advances in cancer treatment, have
served to substantially decrease cancer-related mortality. The
most obvious advances have been made by combining improved
surgical techniques with cytotoxic ionizing radiation and
chemotherapy. Although radiation- and drug-based therapeutic
modalities provide large therapeutic benefit for cancer patients,
physicians are concerned with their adverse side effects. Most
prominent is the risk that patients may develop neoplastic
disorders as a consequence of radio- or chemotherapy. But also
non-neoplastic disorders, such as development of organ failure,
fibrosis or atherosclerosis, are serious health consequences of
cancer therapy. Moreover, development of tumor resistance to
therapy will affect the overall individual outcome of each patient.
One may mitigate these risks by adjusting doses and frequency
of treatment, but this often leads to lower therapy effectiveness
and, consequently, insufficient tumor control. Hence, there is a
growing area for new drug development in the field of supportive
or facilitating agents used in adjuvant therapies, which are
intended to intensify tumor-targeted effects and/or to avert or
minimize treatment-limiting toxicity to normal tissue.
As mentioned above there is experimental and preclinical
evidence that various cysteine cathepsins, particularly, the
cathepsins B, L, and S, are important mediators of cancer therapy
response and outcome in various cancer entities. In this regard,
the modulation of processes that induce cancer cell senescence,
apoptosis or necrosis by cysteine cathepsins in an activating or
inhibiting manner seems to be of particular importance (Cˇesen
et al., 2012; Aits and Jäättelä, 2013). Logically, targeted selective
or multiple inhibitors of cysteine cathepsin activity have been
proposed as promising adjuvant therapeutics forcing cancer cell
death in combined therapeutic regimen (Turk et al., 2012).
This gains importance for internal radionuclide-based or
external radiation therapy as well as for chemotherapeutic
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approaches. Exemplarily, Seo et al. (2009) demonstrated that
irradiation with γ-rays induced overexpression of cathepsin S
both on RNA and protein level in human breast cancer cells
in a dose-dependent manner. This modulation of expression is
mediated by reactive oxygen species (ROS)-interferon-γ (IFN-
γ) pathways. These authors also found the expression of other
cathepsins, in detail cathepsin D, cathepsin L and cathepsin B,
to be induced as a response to ionizing radiation. However, in
their study they focused in particular on cathepsin S functions.
Cathepsin S promoter activity is mediated by the interferon
regulatory factor-1 (IRF1), which binds to a single interferon-
stimulated response element (ISRE) site. This ISRE site is located
100 bp upstream from the transcriptional start site of the
cathepsin S promoter. In an earlier investigation Storm van’s
Gravesande et al. (2002) showed that IFN-γ treatment enhanced
the affinity of IRF1 to cathepsin S IRSE oligonucleotides.
Consistently, Seo et al. demonstrated that radiation-induced
IFN-γ induces IRF1 and, subsequently, increases cathepsin
S promoter activity. As a consequence, high expression of
cathepsin S enhanced the radioresistance of tumor cells and
transfection with cathepsin S-siRNA blocked this effect. These
results are in line with the observation of high cathepsin S
expression in other radioresistent tumors, e.g., glioblastoma
(Flannery et al., 2003, 2006). Notably, radiation response of
cathepsin S also occurred in non-tumorigenic cells (Seo et al.,
2009). The role of cathepsin S in radiation-induced adverse
effects in normal tissues is still unclear. However, it can be
hypothesized that targeted inhibition of cathepsin S as adjuvant
therapy possibly results in both radiosensitization of tumors
and protection of normal tissues. More recently, Malla et al.
demonstrated that cathepsin B increased with X-ray radiation
in a dose-dependent manner in human glioblastoma cells,
thus likewise contributing to radioresistance. Transfection of
these cells with cathepsin B-siRNA resulted in downregulation
of the enzyme and higher radiosensitivity. Of interest, in
this case cathepsin B downregulation contributed to increased
apoptosis rate in the irradiated glioblastoma cells (Malla et al.,
2012). Furthermore, genetic predisposition of tumors can result
in cysteine cathepsin overexpression, thereby contributing to
intrinsic radioresistance or resistance to genotoxic drugs. In
this regard, Grotsky et al. (2013) recently demonstrated that
loss of the tumor suppressor BRCA1 activates cathepsin L-
mediated degradation of the DNA repair factor 53BP1 in human
breast tumor cells. In this study depletion or inhibition of
cathepsin L with vitamin D or the broad-spectrum cysteine
cathepsin inhibitor E64 (6) stabilized 53BP1, which results
in higher genomic instability in response to both radiation
and genotoxic drugs. Consistent with the in vitro experiments,
analysis of human breast tumor samples identified cathepsin L
as a biomarker which inversely correlates with 53BP1 (Grotsky
et al., 2013). This observation is potentially of predictive value for
therapy response of individual patients.
These and also other observations contribute to recent
findings which indicate a potential antiapoptotic function of
cysteine cathepsins in tumor cells. In this regard, enhanced
expression of cathepsin B has been shown to rescue rat
pheochromocytoma cells from apoptosis induced by serum
deprivation (Shibata et al., 1998). On the other hand,
downregulation of cathepsin B using antisense phosphorothioate
oligonucleotides induced apotosis in these cells (Isahara et al.,
1999). Moreover, chemical inhibition of cathepsin B using the
selective dipeptide-derived O-benzoyl hydroxamate 3 in various
highly genotoxic drug- and radiation-resistant human tumor
cells likewise induced apoptosis, which is also contributing to
the hypothesis on antiapoptotic survival-promoting functions
of cysteine cathepsins in human cancer (Zhu and Uckun, 2000).
Accordingly, a study published by Wadhawan et al. (2014)
explains that E64 significantly inhibits filarial cathepsin B activity
followed by generation of oxidative stress and induction of a
mitochondrial mediated apoptosis in filarial parasites (Setaria
cervi). These results suggest that antiapoptotic function of
cysteine cathepsins is not limited to human tissue.
The findings mentioned above are in apparent contradiction
with reports suggesting cysteine cathepsins being mediators of
lysosomal-mediated cell death (Colletti et al., 2012). Exemplarily,
Gores and coworkers demonstrated that cathepsin B contributes
to bile salt-induced apoptosis in rat hepatocytes and rat hepatoma
cells. Both chemical inhibition of cathepsin B using the highly
selective cathepsin B inhibitor CA074 (9a) and expression
of cystatin A prevented cathepsin B activation and apoptosis
during treatment with glycochenodeoxycholate, a toxic bile
salt (Roberts et al., 1997). However, in the context of the
investigation of these authors, the used hepatocyte-derived cell
line McNtcp.24, which is stably transfected with a bile salt
transporter, is more likely a model of hepatocyte injury than of
liver cancer. Consequently, these specific pro-apoptotic functions
of cathepsin B could be interpreted as part of normal tissue
homeostasis. This interpretation is consistent with observations
of the contribution of another cysteine cathepsin, cathepsin L, to
ultraviolet-induced apoptosis in epidermal keratinocytes (Welss
et al., 2003). On the other hand, the observation of increased
glioblastoma cell death in cells transfected with parvovirus H-
1 showing an accumulation of cathepsins B and L in the
cytosol or reduced levels of cystatin B and C, suggests pro-
apoptotic function of cysteine cathepsins also in tumor cells (Di
Piazza et al., 2007). Taken together, it is important to note that
the roles of cysteine cathepsins in cell senescence, lysosomal-
mediated cell death/apoptosis, and necrosis are still not fully
understood. In this regard, various factors that could affect the
suitability of cysteine cathepsin targeting in adjuvant therapeutic
settings must be considered in advance. Particularly, these
factors comprise intracellular localization, such as lysosomal
or cytosolic and extracellular localization, the tissue type as
well as the tumor entity, localization, and microenvironmental
influences.
However, based on the considerations above, inhibition
of cysteine cathepsins also is hypothesized to be a strategy
for chemosensitization or chemopotentiation in a standard or
targeted chemotherapy regimen. Exemplarily, a combination
of doxorubicin and the fluoromethylketone-based cathepsin L
inhibitor 1a enabled the induction of senescence in various
murine and human drug-resistent cancer cell lines (Zheng
et al., 2004). More evidence for chemosensitizing effects due
to cathepsin inhibition has been provided by the same group
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more recently by showing that the cathepsin L-selective aldehyde
inhibitor iCL (compound 11) led to a reversal of resistance
to doxorubicin in human neuroblastoma and osteosarcoma
cells in vitro and in nude mice xenografted with doxorubicin-
resistant human neuroblastoma cells in vivo (Zheng et al., 2009).
With respect to the mechanism of the chemosensitizing action
of this inhibitor, Zheng and coworkers demonstrated that its
use stabilizes and enhances the availability of cytoplasmic and
nuclear proteinaceous drug targets including estrogen receptor-
alpha, Bcr-Abl, topoisomerase-IIα, histone deacetylase 1, and
the androgen receptor. Furthermore, these authors demonstrated
that compound 11 also enhanced the cellular response to
tamoxifen, etoposide, imatinib, vinblastine, and trichostatin A
(Zheng et al., 2009). Of note, this investigation revealed no
chemosensitizing action of 11 on cisplatin. In contrast, there
is experimental evidence that inhibition of cysteine cathepsins
also seems to affect in a positive manner platinum resistance
mechanisms. In this regard, Jacquemont et al. (2012) identified
various compounds that were able to sensitize ovarian cancer
cells to cisplatin. Among them, the tripeptide aldehyde 10 and
the selective irreversible cell-permeable inhibitor CA074Me (9b)
substantially synergized with cisplatin. Of note, the platinum
resistance mechanisms investigated was monoubiquitination and
nuclear foci formation of FANCD2, a crucial step in the so-
called Fanconi anemia pathway. In addition to the in vitro data,
a combination regimen of “chemo-switch” cyclophosphamide, a
DNA-alkylating agent, and cysteine cathepsin inhibition using
the cell-permeable broad-spectrum inhibitor JPM-OEt (7b) was
demonstrated to be very effective in preclinical trials, as it
reduced the tumor burden and extended the survival in a
RIP1-Tag2 mouse model of pancreatic islet cell carcinogenesis
(Bell-McGuinn et al., 2007). Conversely, combined treatment
of mouse lymphosarcoma using cyclophosphamide and E64c
(8a) stimulated tumor growth and reduced the antitumor
effect of cyclophosphamide (Zhanaeva et al., 2005). These
again contradictory results contribute to a critical analysis of
the benefit of combining cysteine cathepsin inhibitors with
chemotherapeutics. However, such adjuvant therapeutic settings
targeting cysteine cathepsins will not only affect tumor cells but
also stromal cells and microenvironment-supplied factors. In
this regard, stromal cells such as tumor-associated macrophages
become an important target. Tumor-associated macrophages are
abundant suppliers of cysteine proteases, which are important
for enhancement of tumor growth and invasion (Small et al.,
2013; Bengsch et al., 2014). Furthermore, macrophages provide
survival signals to tumor cells in a cathepsin-dependent manner,
which abrogates tumor cell death induced by various stimuli.
Such “chemoprotective” effects of cathepsins were identified
for taxol, etoposide, and doxorubicin. Logically, inhibition of
cathepsin activity is sufficient to minimize or abrogate this
protective effect, as demonstrated in breast cancer, for example
(Shree et al., 2011). Of interest, therapeutical approaches that
exert effects on activity and localization of cysteine cathepsins in
an indirect manner also may result in chemosensitization. This
has been demonstrated very recently in human hepatocellular
carcinoma cells for which suppression of CD47 by a morpholino
approach exerted a chemosensitization effect through blockade of
cathepsin S/protease-activated receptor 2 (PAR2) signaling (Lee
et al., 2014).
On the other hand, inhibition of cysteine cathepsins in
cancer patients may not always be desirable and will strongly
depend on the type of chemotherapeutic drug. Exemplarily,
to overcome dose-limiting side effects of doxorubicin-like
cardiotoxicity, an intensive effort has been undertaken to
develop promising doxorubicin peptide prodrugs targeted to,
e.g., cysteine cathepsins that are specifically activated at the tumor
site (see Section Substrate-based Probes). The addressed cysteine
cathepsins, particularly, cathepsin B, then catalyze the activation
of these prodrugs, and hence, the regulation of this enzyme by
antitumor agents could influence the efficacy of these peptide
prodrugs (Bien et al., 2004; Zhong et al., 2013).
Potential adverse or side effects that may accompany
inhibition of cysteine cathepsins are more generally to be
regarded as limiting criteria. Exemplarily, inhibition of cathepsin
B and L results in lysosomal dysfunction and consequent cell
death in pancreatic β-cells (Jung et al., 2015), but it is beyond the
scope of this review to discuss this in more detail.
Recent Trends in the Development of
Cysteine Cathepsin-targeting Imaging
Probes and Related Molecular Tools
The increasing insight into the functions of the cathepsins has
also raised interest to follow their actions in living systems by
molecular imaging and both fields have mutually stimulated
each other. The most relevant imaging modalities that can
provide information on the molecular level are optical imaging
(OI), single photon emission computed tomography (SPECT),
positron emission tomography (PET) and magnetic resonance
imaging (MRI) (Quillard et al., 2011; James and Gambhir, 2012;
Cunha et al., 2014). The principles of optical imaging will be
briefly outlined below, those of SPECT and PET in Section
Radiotracers.
Because MRI relies on the phenomenon of nuclear magnetic
resonance (NMR), it bears a great potential to obtain biochemical
information. One approach to generate molecular contrast in
MRI is based on chemical exchange saturation transfer (CEST).
This method relies on proton exchange between acidic or basic
functionalities and bulk water. Provided that the rate constant
of exchange does not exceed the difference in the resonance
frequencies of the chemical entity and water, presaturation of the
respective protons in the solute by an appropriate radiofrequency
pulse will result in saturation transfer to bulk water (Woods
et al., 2006; van Zijl and Yadav, 2011). In consequence, the
NMR signal of the water protons will be attenuated and thus
negative contrast is generated. Very recently, this principle
has been applied to image the tumor-associated cathepsin B
activity in a rat brain tumor model using poly-L-glutamate as
contrast-generating agent (Haris et al., 2014). This syngeneic
orthotopic tumor model is derived from 9L rat gliosarcoma cells,
which express active cathepsin B. Because hydrolysis of poly-L-
glutamate catalyzed by cathepsin B releases exchangeable amine
protons, the CEST contrast will increase upon enzymatic action.
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Ninety minutes after injection of poly-L-glutamate the CEST
signal in the tumor region increased by 19%. Despite the potential
to detect chemical changes and high spatial resolution, MRI
lacks sensitivity compared to the other imaging modalities. For
example, a dose of poly-L-glutamate as high as 160mg/kg had to
be injected into rats for CEST imaging of cathepsin B.
In general, the field of molecular imaging depends on the
development of compounds consisting of moieties that can
generate detectable signals in addition to the entity that mediates
biological targeting. Such molecular probes are not restricted to
be used in whole-animal imaging but are also valuable tools for
in vitro and in cellulo investigations.
Fluorescent Probes
OI relies on the detection of low-energy photons that can be
emitted by processes of fluorescence, chemiluminescence and
bioluminescence and, furthermore, by Cˇerenkov radiation (see
Section Radiotracers). Concerning OI of cysteine cathepsins, the
reported probes are based on fluorescently labeled substrates
and inhibitors. The instrumental setup for fluorescence imaging
basically consists of a light source for illumination and a
charged coupled device (CCD) camera for detection of the
emitted light. Therefore, the required instrumentation is rather
inexpensive compared to other imaging modalities. Because the
penetration depth of visible light in tissue is limited to only a few
centimeters, whole-body OI is restricted to small animals such
as mice and rats. Penetration depths are highest for fluorophores
that emit photons in the near-infrared region (650–900 nm) of
the electromagnetic spectrum. Concerning clinical translation,
issues related to penetration depth can be circumvented by
applying endoscopic imaging systems (James and Gambhir,
2012). Generally, the advancement in the field of OI is dependent
on the engineering of fluorophores with favorable photophysical
properties and the development of methods for their chemical
conjugation (Kim and Park, 2010; Grimm et al., 2013).
Because cysteine cathepsin-targeting fluorescent probes are
covered by other review articles, only recently reportedmolecular
probes of this category will be discussed herein (Blum, 2008;
Edgington et al., 2011; Hu et al., 2014b; Sanman and Bogyo,
2014).
Activity-based Probes
Particular attention has been devoted to the development of
probes based on inhibitors which form stable covalent bonds
with the active-site cysteine. These molecular probes are referred
to as activity-based probes (ABPs) (Schmidinger et al., 2006;
Paulick and Bogyo, 2008; Willems et al., 2014). Besides the
electrophilic warhead that enables covalent targeting of the active
site, these probes consist of a tag containing the reporter group,
which allows the detection of the enzyme-inhibitor complex,
and a linker. The linker not only connects the warhead with
the reporter tag but also confers selectivity by giving rise to
non-covalent interactions in the enzyme’s binding pockets. Apart
from fluorophores that enable fluorescence imaging, reporter
groups may be built of affinity tags such as biotin, radionuclide-
containing groups (see Section Radiotracers) or moieties
modified with non-abundant stable isotopes (Sadaghiani et al.,
2007; Serim et al., 2012).
More than for in vivo imaging, ABPs have been used to detect
active proteases in cell lysates by incubating the crude protein
mixtures with the labeled probes and subsequent electrophoretic
separation followed by label-specific detection. This approach
is called activity-based or chemical proteomics and offers the
advantage of coupling the detection signal to enzyme activity
and therefore provides more accurate information about the
functions of the enzyme of interest in the biological process
to be studied (Fonovicˇ and Bogyo, 2008; Deu et al., 2012).
A recently developed ABP to target cathepsin K is compound
14 (Figure 6) (Frizler et al., 2013). This probe is based on
the vinyl sulfone warhead and equipped with an innovative
tricyclic luminescent group which represents a conformationally
restricted analog of the 4-(4-hydroxybenzylidene)-1H-imidazol-
5(4H)-one fluorophore in green fluorescent protein (Baranov
et al., 2012). Compound 14 proved to be an irreversible
inactivator of the cathepsins S, K, L, and B with a slight
selectivity toward S and K over L and B, while it showed
the strongest potency against cathepsin S. Its suitability to
visualize cathepsin K ex vivo by in-gel fluorescence imaging
after electrophoretic separation of the cathepsin K-14 complex
has been demonstrated. Labeling of cathepsin K by 14 could
be prevented upon preincubation with a reversible azadipeptide
nitrile inhibitor that is highly selective for this cathepsin. The
probe enabled the detection of external cathepsin K among
the proteins present in HEK cell lysate. A linear correlation
between the fluorescence intensity of the electrophoretic spots
and the amount of enzyme was observed over a range of 17–
280 ng of cathepsin K and the detection limit was found to be
superior to Western blot. The ABP 15 is of very similar design
as 14 (Mertens et al., 2014). In contrast, it is equipped with
an alternative fluorophore on the basis of a novel coumarin-
tetrahydroquinoline hybrid. This fluorophore can be considered
as a conformationally locked 7-N,N-diethylaminocoumarin and
shows improved photophysical properties over its non-rigidified
counterpart such as bathochromically shifted absorption and
emission maxima (Frizler et al., 2012; Mertens et al., 2014).
Among the cathepsins S, K, L, and B, inactivation by 15 was
strongest for cathepsin S with approximately threefold increased
kinact/KI-values for this cathepsin compared to compound 14.
Probe 15 is more than 50-fold less potent for cathepsin K than
for S. This result has been explained on the basis of docking
studies, which revealed that the coumarin-tetrahydroquinoline
moiety of 15 partially occupies the S3 pocket of cathepsin S and
its position is probably stabilized by hydrogen bond interactions
between its two carbonyl groups and the side chain of Arg141
and the backbone NH of Val162. This aptly illustrates that
also the fluorophore may interact with the enzyme and thus
can contribute to the selectivity of the probe. Compound 15
was evaluated for in-gel detection of cathepsin S in a similar
fashion as 14 for cathepsin K. The fluorescent cathepsin S-15
complex enabled to visualize enzyme amounts as low as 0.5 ng.
Preincubation of cathepsin S with the broad-spectrum cysteine
protease inhibitor E64 (6) abolished its labeling by 15, which
shows that inactivation is dependent on the catalytic activity
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FIGURE 6 | Fluorogenic ABPs targeting cysteine cathepsins. Emitting fluorophoric moieties are shown in red, chromophoric moieties that act as quencher are
highlighted in green.
and labeling does not occur due to indiscriminate reaction with
nucleophiles on the protein surface. In addition, ABP 15 has been
shown to be capable of detecting cathepsin S specifically in a
protein extract derived from human placental tissue.
The fluorophores employed in the ABPs 14 and 15
compromise their application for in vivo imaging, because
their emission wavelengths are too short to ensure a sufficient
light penetration from deeper tissues (James and Gambhir,
2012). Significant progress toward optical imaging of cysteine
cathepsins has been achieved by using ABPs based on
acyloxymethyl ketones. As this class of irreversible inhibitors
interacts with the active-site thiol by nucleophilic substitution,
they offer the opportunity to combine the fluorescence donor
with a quencher that can be attached to the leaving group. Förster
resonance energy transfer (FRET) in the unreacted probe will
result in a strongly attenuated fluorescence of the unreacted
probe, while the quencher leaves the enzyme-inhibitor complex
upon inactivation which leads to enhanced luminescence of
the donor. Consequently, target binding is coupled to signal
amplification, whichmay account for good signal-to-noise ratios.
Recently described probes of this type are compounds 16a
and 16b. In 16a, the commonly employed 2,6-dimethylbenzoyl
moiety has been replaced by an electron-deficient 2,3,5,6-
tetrafluorophenyl moiety in order to eliminate the potentially
metabolically unstable ester linkage and to increase electronically
and sterically the reactivity against the active-site cysteine
(Verdoes et al., 2013). Both ABPs are equipped with a Cy5-
derived fluorescence donor attached to the P1 position and Sulfo-
QSY21 as quencher, which is tethered via an amide group and
ethylene diamine or hexamethylene diamine linker to the para
position of the tetrafluorophenyl or 2,6-dimethylbenzoyl group,
respectively. The in vitro evaluation of 16a was performed in
RAW 264.7 cells, a mouse leukemic monocyte macrophage cell
line, on the basis of in-gel fluorescence readouts in comparison
to seven analogs that varied in the sulfonation of the QSYmoiety,
the chain length of the diamine linker and/or contained a 2,6-
dimethylbenzoyl instead of the 2,3,5,6-tetrafluorophenyl moiety.
It was observed that the presence of the sulfonic acid function at
the QSY chromophore accounts for superior performance with
regard to labeling of cysteine cathepsins in intact cells, while the
change of the ethylene spacer to hexamethylene in the diamine
linker impairs the probe’s performance only to a minor extent.
Furthermore, more hydrophobic analogs showed low level in-
gel fluorescence signals that reached a maximum intensity
at concentrations of 0.5–1.0µM, which has been interpreted
in terms of probe aggregation due to limited solubility. In
contrast, 16a showed brighter signals for the different cysteine
cathepsins that increased up to a concentration of 5µM. When
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the 2,3,5,6-tetrafluorophenyloxymethyl ketones were compared
to their 2,6-dimethylbenzoyl-based counterparts it was obvious
that the former type of probe led to a more uniform labeling
of the cathepsins L, S, and B while the acyloxymethylketones
reacted preferentially with cathepsin S and L. Surprisingly, the
2,3,5,6-tetrafluorophenyloxymethyl ketones were even capable of
labeling cathepsin X, a papain-like cysteine protease which is
generally difficult to target with inhibitors. It has been shown
that concentrations of 16a as low as 5 nM are sufficient to
detect cathepsins L, S, B, and X in RAW 264.7 cell lysates.
According to the authors, this phenomenon probably reflects
the cellular localisation of the various cathepsins rather than
differences in molecular recognition between the probe and the
enzymes, as cathepsin X is supposed to reside on the cell surface.
The investigation of the time course of cathepsin labeling by
16a in live RAW 264.7 cells indicated that a rapid labeling
of cathepsin X occurred, followed by cathepsins S, L, and B.
Pretreatment of the RAW 264.7 cells with an excess of JPM-
OEt (7b), a cell permeable “prodrug” of an irreversible inhibitor
of the epoxysuccinyl chemotype, resulted in reduction of the
in-gel fluorescence to 10% of the original signal. Preexposure
of 16a to serum for 4 h retained 80% of the cathepsin-
targeting potential. In contrast, the identical treatment of the
corresponding AOMK-based probe diminished the fluorescence
signals associated with electrophoretic bands by 70%, which
might due to hydrolytic cleavage of the ester linkage catalyzed
by serum esterases. ABP 16a was also investigated toward
human monocyte-derived macrophages and a similar labeling
profile was observed as in the murine cell line. Fluorescence
microscopy studies with the human macrophages and 16a led
to red fluorescence in cell regions that have been identified as
lysosomes. This signal was completely blocked in the presence of
JPM-OEt (7b). The potential of 16a for in vivo imaging of tumor-
associated cysteine cathepsins was evaluated in a syngeneic
orthotopic mouse model of breast cancer derived from murine
4T1 cells. Already 1 h post injectionem (p.i.) the margins of
the tumor were visible with substantial contrast. Compound
16a gives rise to a fluorescence signal in the tumor region
whose intensity at 8 h p.i. was approximately 20-fold higher than
that of its desulfo-hexamethylene-2,6-dimethylbenzoyl-based
counterpart. This result was confirmed by ex vivo fluorescence
measurements and reflects the in vitro performance of this
probe. The in vivo targeting of cathepsins L, S, B, and X has
been demonstrated by SDS-PAGE of the tumor homogenates.
Interestingly, immunofluorescence staining for the macrophage
marker CD68 in tissue sections from tumors pretreated with 16a
has revealed that labeling by the probe occurs almost exclusively
in tumor-associated macrophages.
Furthermore, ABP 16a has been evaluated in orthotopic
mouse models of familial adenomatous polyposis and colitis-
associated colorectal cancer (Segal et al., 2015). Upon intravenous
injection of the probes, fluorescence accumulated in the
malignant polyps but not in the surrounding benign intestinal
tissue. The signal correlated well with the polyp diameter and
was significantly lower under pre-treatment with compound 4.
For the colitis-relatedmodel of colon cancer the contrast between
malignant and normal tissue was higher upon intra-rectal
administration compared to intravenous injection. In this model
of colon cancer, mainly cathepsin S was targeted by 16a, as
revealed by SDS-PAGE. Fluorescence microscopy on murine
colon tissue sections indicated the colocalization of the probe
with the immune cell marker CD45. Fluorescence micrographs
obtained in immunohistochemical analyses of tissue sections
derived from human colon polyps confirmed these results.
The motivation behind the design of compound 16b was
to achieve selective imaging of cathepsin S in the presence of
other cysteine cathepsins. To this end, a fragment consisting
of a 3-thenoyl cap and a trans-4-methylcyclohexyl residue to
address the S2 pocket of cathepsin S have been employed in
this compound (Oresic Bender et al., 2015). The peptide bond
that connects the P2 and P1 moieties is replaced by a 1,4-
disubstiuted triazole. This dipeptide-mimicking fragment has
been identified to confer excellent selectivity to cathepsin S over
the cathepsins B, K, and L (Patterson et al., 2006). Because
the tetrafluorophenoxymethyl ketone warhead was found to
be unfavorable regarding the selectivity toward cathepsin S,
the 2,6-dimethylbenzoyl leaving group in combination with a
hexamethylene diamine linker was employed. Incubation of
RAW 264.7 cells with 16b and subsequent analysis of cell
lysates by SDS-PAGE confirmed its selectivity for cathepsin S
over cathepsins B, L, and X. The probe was evaluated in the
4T1 murine breast cancer model. Tumor-associated fluorescence
was clearly detectable 8 h p.i. but the intensity was 6 times
reduced compared to 16a, which reflects the selectivity of 16b for
cathepsin S. The probe’s cathepsin S selectivity has been exploited
for dual-color live cell cysteine cathepsin activity imaging in
bone marrow-derived macrophages and dendritic cells. For this
purpose, a pan-reactive green-emitting probe was prepared in
which the Cy5 and Sulfo-QSY21 moieties of 16a were replaced
by BODIPY FL and BHQ-10, respectively. The immune cell
lines were simultaneously incubated with this probe and 16b
at optimized concentrations for 2 h. Dual-color fluorescence
microscopy revealed that cathepsin S colocalized with other
cysteine cathepsins in the macrophage line while compartments
that exclusively harbor cathepsin S seem to exist in dendritic cells
(Oresic Bender et al., 2015).
Substrate-based Probes
The concept of activatable fluorescence is easy to realize in
substrates as hydrolysis of the peptide bond will lead to two
cleavage products which will dissociate from each other. The
advantages and disadvantages that are associated with the use
of activity- or substrate-based probes for non-invasive optical
imaging of the tumor-associated cysteine cathepsins have been
exemplarily compared. It was concluded from this study that
fluorescent ABPs exhibit more rapid and selective uptake into
tumors as well as stronger signal contrast compared to substrate-
based probes (Blum et al., 2009).
However, the latter-type of imaging agents offer the potential
advantage of enzyme-mediated signal amplification. A recently
reported substrate-based probe is compound 17, which has
been developed for the imaging of tumor-associated cathepsin
S (Figure 7) (Hu et al., 2014a). The compound has been
designed on the basis of a potent cathepsin S inhibitor bearing
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FIGURE 7 | Quenched substrate-based probes for optical imaging of cysteine cathepsins. Emitting fluorophoric moieties are shown in red, chromophoric
moieties that act as quencher are highlighted in green and additional targeting moieties are shown in blue.
cyclohexylalanine in P2 and a cyclic ketone in the P1 position.
The ketone moiety gives rise to a reversible covalent interaction
with the active-site cysteine by thiohemiketal formation. The N-
terminal amino group of this dipeptide derivative is connected
to a morpholine moiety via a urea linkage. A morpholino group
in this position will be engaged in favorable interactions with the
side-chain of Lys64 in the S3 region of cathepsin S via its oxygen
atom (Pauly et al., 2003). Furthermore, cyclohexylalanine has
been identified to be optimal to address the S2 pocket of cathepsin
S (Ward et al., 2002). The combination of these two favorable
moieties makes this inhibitor highly selective for cathepsin
S (Link and Zipfel, 2006). In order to convert the inhibitor
into a substrate and to allow the attachment of fluorophores
and further targeting elements, the cyclic ketone in the P1
position was replaced by diaminobutyric acid. Such a strategy
to design selective protease substrates starting from covalent
inhibitors is termed reverse design. This concept seems to be
promising because small peptide-derived inhibitors very often
were structurally optimized using non-proteinogenic amino
acids to achieve optimal targeting of protease subsites. It has been
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successfully applied for the design of optical imaging probes for
cathepsin K and cathepsin S (Watzke et al., 2008). By employing
lysine with orthogonally protected amino groups a Cy5.5 as
NIR fluorophore and a palmitoyl group was attached to the
diaminobutyric acid in the P1 position. Palmitoylation of the
probe was done with the intention to facilitate its localisation
to the cell surface, because the secreted cathepsin S will remain
in proximity to the cellular membrane. Via an ethylenediamine
linker the chromophore of black hole quencher 3 (BHQ-3)
was attached as dark quencher to silence the Cy5.5 reporter.
The kinetic characterisation of the substrate-based probe 17
toward hydrolysis catalyzed by the cathepsins B, K, L, S, and
V has revealed that it is selectively cleaved by cathepsin S with
a specificity constant kcat/Km of 2700 M−1s−1. Interestingly,
the cathepsin S-catalyzed hydrolysis of 17 was significantly
enhanced in the presence of liposomes as membrane model.
Microscopic evaluation of compound 17 together with its non-
lipidated counterpart containing a maleimidylhexanoyl group
instead of palmitoyl was done toward human THP-1 cell-
derived macrophages. The studies indicated that both probes
were cleaved rapidly by the cells and associated with them.
Preincubation with cell-impermeable E64 (6) resulted in blocking
of the cleavage of 17 only, whereas that of the non-lipidated
probe was not influenced. In contrast, treatment with E64d
(8b), a cell-permeable analog of E64 prevented the hydrolysis
of both probes, which indicates that they are not recognized as
substrates by other proteases. These results have been interpreted
to indicate that the palmitoylated probe undergoes hydrolysis
catalyzed by surface-located cathepsin S, whereas the non-
lipidated probe is subjected to internalization before it is cleaved.
Because compound 8b inhibited the activation of both probes,
they are probably not recognized as substrates by other proteases,
and thus, cleaved by cathepsin S in a highly specific manner.
Performing the experiment at 4◦Cdid not lead to activation of the
non-lipidated probe, whereas the signal from activation of 17was
restricted to the cell membrane due to attenuated endocytosis.
In vivo evaluation in 4T1 tumor-carrying mice revealed that for
both probes a significant fluorescence signal was observable in
the tumor 30min p.i. that did not vanish up to 24 h p.i. At his
time the signal caused by 17 was as twice as high compared
to its non-lipidated counterpart. The tumor-muscle ratio of 17
reached a maximum of 18 after 5 d p.i. The non-lipidated
probe was also detectable in the kidneys, whereas the uptake
in other organs was very low. Compound 17 is taken up by
the kidneys to a similar extent as its non-lipidated counterpart,
whereas lipidation resulted in a significantly higher uptake in all
other investigated organs (lung, liver, spleen), but the levels were
greatest for the tumor. The significantly increased tumor uptake
of 17 compared to the non-lipidated probe was confirmed in ex
vivo investigations of tumor sections by fluorescence microscopy
(Hu et al., 2014a).
A probe of similar composition as 17 is compound 18, which
has been described by Tian et al. (2014). The similarity is
due to the fact that 18 contains a pteroyl group as targeting
unit additional to the cathepsin cleavage site, in analogy to
the palmitoyl residue of 17. In difference, probe 18 has
been designed to primarily target the folate receptor by the
pteroylglutamyl group. The cellular uptake of folic acid and its
derivatives is mediated by two transport systems, the reduced-
folate carrier (SLC19A1) and the glycosyl phosphatidylinositol
(GPI)-anchored membrane folate receptors α (FOLR1) and
β (FOLR2). While the former is expressed ubiquitously and
facilitates bidirectional diffusion of folates across the plasma
membrane, the latter affect the unidirectional uptake of folic acid
by receptor-mediated endocytosis via the endosomal recycling
pathway (Shen et al., 1997; Matherly et al., 2007). Folate receptor
expression in homeostasis is restricted to the lung, kidneys and
placenta. An overexpression of the folate receptor can occur in
neoplastic tissue, especially epithelial cancers such as ovarian,
colorectal, and pancreatic carcinoma (Assaraf et al., 2014).
The design of probe 18 aims at coupling the targeting of
folate receptor to activation by intracellular cathepsin B upon
receptor-mediated internalization. Compound 18 is constituted
by the peptidic cathepsin-responsive core moiety harboring
valine and citrulline to target the S2 and S1 subsites of cathepsin
B, respectively. To target the primed binding regions, ornithine is
employed, which is connected to citrulline via its δ-amino group.
Notably, ornithine can be considered as dipeptide mimetic in this
context, as its carboxy group might be able to target the histidine
residues in the occluding loop. Equipped with fluoresceine
conjugated to a lysine side chain, the probe is quenched in the
uncleaved state by Förster resonance energy transfer to a dabcyl
group, which is attached at the α-amino group of ornithine.
The folate group has been linked to the N-terminus via the
side chain of its glutamate moiety. Exposure of 18 to cathepsin
B (400 nM) resulted in a 10-fold increase in fluorescence due
to dequenching upon cleavage within 250min. The compound
has been characterized to be stable in blood plasma for at least
24 h, which favors its in vivo application. The cell uptake of 18
has been studied with KB cells, a human epidermoid carcinoma
cell line expressing the folate receptor, using FACS analysis.
The uptake has been confirmed to be concentration-dependent
and the cellular fluorescence was much lower when the folate
group of 18 was replaced by an acetyl residue. Furthermore,
preincubation of the KB cells with 50µM folic acid reduced
the fluorescence by approximately 70%. In accordance with this
result, the uptake of 18 was clearly reduced when cells expressing
low levels of the folate receptor such as MCF-7 breast cancer
cells and mouse embryonic fibroblasts were used instead of KB
cells. The intracellular activation of the probe was demonstrated
by repeating the FACS analysis at 0◦C together with the analog
lacking the dabcyl group. The fluorescence intensity of the
cells incubated with 18 was articulately reduced over the ones
treated with its unquenched counterpart, because the ATP-
consuming internalization of the probe-folate receptor complex
is attenuated at this temperature. The intracellular activation of
18 was furthermore confirmed by microscopic studies in KB
cells, as after 30min green fluorescence at the cell surface was
only observable for the unquenched counterpart and not for
compound 18. The microscopic investigations also revealed an
unspecific binding for the folate lacking analogs of 18 at higher
concentrations (200 nM). This finding has been attributed to the
hydrophobic character of the fluoresceine and dabcyl groups and
indicates a general drawback of optical imaging probes, because
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the bulkiness and hydrophobicity of the required chromophores
may negatively influence their behavior in biosystems (Tian et al.,
2014).
Despite quenched substrates offer the advantage of enzyme-
catalyzed signal amplification, substrate-based imaging is also
possible with probes that contain a fluorogenic leaving group
in the absence of a quencher. This principle is based on the
deactivation of substituents that exert a +M effect on the
aromatic core of fluorophoric entities by the attachment of acyl
groups to these substituents. Cleavage of those acyl groups by the
action of enzymes will result in unblocked electron donation to
the fluorophore and thus increased fluorescence. This principle
has been used extensively for the activity determination of
proteases and other enzymes that catalyze acyl transfer reactions
(Grimm et al., 2013) while reports concerning their application
for imaging purposes are scarce. Probes of this type that have
been recently developed for cellular imaging are compounds
19 and 20 (Figure 8). Development of compound 19 started
from the established dipeptidic fluorogenic substrate Z-Arg-
Arg-AMC, which is sensitive and selective for the fluorimetric
detection of cathepsin B activity. For the sake of better synthetic
accessibility, its two arginine residues were replaced by lysines.
This structural change had almost no influence on the kcat/Km-
values (148 and 167mM−1s−1 for Z-Lys-Lys-AMC and Z-
Arg-Arg-AMC, respectively). To increase the stability toward
degradation by other proteases and the affinity toward cathepsin
B a para-aminobenzyloxycarbonyl (PABA) linker was placed
between the peptidic and AMCmoiety, as this will enable a more
effective targeting of the primed binding sites (presumably S1
′
and S2
′
) of cathepsin B (Chowdhury et al., 2014). PABA is a
FIGURE 8 | Fluorogenic substrate-based probes for targeting of cysteine cathepsins containing only one luminophor. Emitting fluorophoric moieties are
shown in red, moieties that act as spacer are highlighted in green and additional targeting moieties are shown in blue.
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self-destructive linker, as release of its amino group will result
in spontaneous fragmentation due to imino-quinone methide
formation, which has been successfully used for prodrug design
(Carl et al., 1981). Indeed, 19 showed a slightly increased kcat/Km-
value (231mM−1s−1) than Z-Lys-Lys-AMC, which seems to be
due to a decrease in Km. Noteworthy, the introduction of the
PABA linker was not tolerated by cathepsin L as the analog of
19 containing Phe instead of Lys in P2 (Z-Phe-Lys-PABA-AMC)
was not converted by this enzyme. Therefore, the combination of
the two Lys residues with the self-destructive PABA linker makes
19 to a substrate which is cleaved by cathepsin B with excellent
selectivity over cathepsins L and S. Probe 19 was also effectively
cleaved by lysates of HeLa cervical tumor cells. Pretreatment
of HeLa cells by the cell-permeable pro-inhibitors E64d (8b)
or CA074Me (9b), which inhibit several cysteine cathepsins or
selectively cathepsin B, respectively, after intracellular activation
by esterases, resulted in a complete blocking of the conversion of
19. Fluorescencemicroscopic observation of live HeLa cells in the
presence of Z-Arg-Arg-AMC or Z-Phe-Arg-AMC did not result
in the detection of any cellular fluorescence. Contrary to this,
the three-component probe 19 containing the PABA linker led to
blue fluorescent cells, while no intracellular fluorescence could be
visualized in the presence of CA074Me (9b) or E64d (8b). Similar
results were obtained when the HeLa cells were replaced by the
Her2-positive breast cancer cell line MDA-MB-231-H2N. These
results clearly indicate that 19 undergoes cathepsin B-dependent
activation inside the cells and that the PABA linker obviously
facilitates membrane permeation of the peptidic probe. When
Z-Phe-Lys-PABA-AMC was investigated in the same manner,
it was revealed that its cellular activation was only completely
blocked by treatment with E64d, while the presence of CA074Me
resulted in considerable residual cellular fluorescence. These
observations suggest that the latter probe is activated by cathepsin
B and other cysteine cathepsins, which is in accordance to
results from kinetic investigations and cell lysate experiments.
Furthermore, Z-Phe-Lys-PABA-AMC compromises cell viability
in both cell lines as assessed by the MTT assay, while 19 and
the ordinary two-component probe Z-Arg-Arg-AMC are well-
tolerated (Chowdhury et al., 2014).
While 7-amino-4-methylcoumarin is an advantageous
fluorophore for protease activatable probes due to its small size,
its blue fluorescence and rather short excitation wavelength are
adverse properties. Alternatives can be found by rhodamine
derivatives, which exhibit two amino groups attached to the
xanthenyl system and offer the opportunity of longer wavelength
excitation/emission together with high quantum yields for
fluorescence. Peptidic moieties can be attached to the two
amino groups of rhodamines which will result in fluorescence
attenuation and illumination upon protease-mediated cleavage
(Leytus et al., 1983; Rothe et al., 1992). However, a drawback
of such probes is that consecutive removal of two peptide
residues will result in mono-acylated and completely deacylated
rhodamine species which will differ in their fluorescence
properties. To tackle that problem, Fujii et al. (2014) developed
activatable probes based on “reduced” rhodamine green
(rhodamine green is also known as rhodamine 110), in which
the carboxy group is replaced by a hydroxymethyl residue.
Typical for xanthene dyes, this hydroxymethyl rhodamine
green (HMRG) exists in solution in a ring-chain tautomeric
equilibrium between a non-fluorescent spirocyclic form and
a highly fluorescent quinoid open form. At physiological pH,
the equilibrium lies on the side of the open form, which is
characterized by favorable photophysical properties such as high
fluorescence quantum yield (8fl = 0.81) and long fluorescence
lifetime (τ = 3.8 ns) (Sakabe et al., 2013). Mono-acylation of one
of the amino groups will stabilize the non-fluorescent spirocyclic
form and thus result in strong attenuation of fluorescence. Fujii
et al. aimed to exploit this principle for the design of cathepsin
B-activatable probes in the context of optical tumor imaging. To
this end, they attached the Z-Phe-Arg (as realized in compound
20) and Z-Arg-Arg moiety to HMRG. The extinction coefficient
of free HMRG is more than 400 times higher than that of 20 (at
λmax = 501 and 497 nm, respectively). The kinetic evaluation
toward the cathepsins L, B, S and K was done at pH 5.5 and pH
7.4, to simulate intralysosomal and cytosolic/extracellular pH-
values, at a single substrate concentration of 3µM. Cathepsin
B rapidly converted 20 at both pH-values, whereas the cleavage
of Z-Arg-Arg-HMRG was only effective at pH 5.5. At this
pH conversion of 20 by cathepsin L was slower than that by
B, whereas Z-Arg-Arg-HMRG was cleaved with much lower
velocity. The cleavage of 20 catalyzed by cathepsin L at pH 7.4 was
very slow, probably due to the fact that cathepsin L undergoes
irreversible inactivation at pH-values greater than 6.5 (Brömme
et al., 1993). Compound 20 was also converted by cathepsin K
at both pH-values but was no effective substrate of cathepsin
S. Incubation of 20 with SK-OV-3 human ovarian tumor cells
resulted in microscopically visible cell-associated fluorescence,
which was attenuable by treatment with the broad-spectrum
cell-permeable fluoromethylketone inhibitior Z-Phe-Phe-FMK
(1a). It was concluded that cleavage of 20 occurs intracellularly,
because the treatment with membrane-impermeable inhibitor
CA074 (9a) was of negligible influence. Intraperitoneal injection
of 20 into mice bearing peritoneally implanted SK-OV-3
tumors, a model for human ovarian cancer, resulted in a clear
visualization of the tumor nodules with a tumor-to-background
ratio of 4.2 The stability of 20 in peritoneal liquid has been
confirmed independently and the green HMRG fluorescence
colocalized with the tumor nodules when SK-OV-3 cells
transformed with red fluorescent protein (RFP) were implanted.
The disadvantages of the discussed non-quenched cathepsin-
responsive probes are due to the fact that the emission
wavelengths of their fluorophores are too short for in vivo
imaging. Fluorophores with emission wavelengths in the near
infrared (NIR) range can be found within the class of
cyanine dyes, which are employed in the FRET-based probes
16 and 17 discussed above. Despite these fluorophores are
characterized by high extinction coefficients, acylation-based
attenuation of fluorescence is difficult to realize, in contrast
to luminescent groups on the basis of aromatic amines such
as AMC and HMRG. To overcome this drawback, Kisin-
Finfer and Shabat (2013) set out to develop fluorophores where
three consecutive carbons of the polymethine chain of cyanine
dyes are part of a napthalene ring. To this end, they reacted
4-hydroxynaphthalene-1,3-dicarbaldehyde with two equivalents
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of 3-(2,3,3-trimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate
in a Knoevenagel-type condensation. The obtained product is a
representative of the so called “donor-two-acceptor” NIR dyes,
referring to the electron-donating hydroxyl group and the two
indolium acceptor moieties (Karton-Lifshin et al., 2012), and
shows a pH-dependent fluorescence with an emission wavelength
of 740 nm and a large Stokes shift of 80 nm. Notably, only the
deprotonated phenolate form is fluorescent. In consequence,
acylation of the OH group will lead to strongly attenuated
fluorescence, which can be exploited to design hydrolase-
sensitive probes as it has been realized in compound 21 for
imaging of cathepsin B (Kisin-Finfer et al., 2014). Considering
the steric demand of the fluorophore, its conjugation to the
cathepsin-responsive Z-Phe-Lys moiety was done via a self-
immolative linker which resembles in part the PABA linker
contained in 19 (Chowdhury et al., 2014). In difference, a N,N’-
dimethylethylenediamine-carbonyl spacer follows the PABA
element (Shabat et al., 2004). Analogously to 19, cathepsin
B-mediated release of the aromatic amine will result in the
formation of imino quinone methide and carbon dioxide. This
reaction step triggers in turn the release of the phenolic hydroxyl
group via cyclisation by attack of the secondary amine nitrogen
to the carbamate carbon under concomitant formation of a five-
membered cyclic urea. Apart from creating space between the
fluorophore and the cleavage site, this strategy ensures that the
two functional entities are joined by sufficiently stabile amide
and carbamate linkages instead of a labile aryl ester bond.
Based on visual inspection, incubation of 21 with rather high
concentrations of cathepsin B led to a strong red fluorescent
solution after 4 h upon excitation at 661 nm, while no background
luminescence was observable in the absence of the enzyme. This
result is in contrast to the analogous quenched (FRET-based)
probe, which has been designed to contain a Cy5 fluorophore
in place of the Z group and a heptamethine-cyanine dye as
quencher attached via the PABA linker. In consequence, the
in vivo performance of 21 upon intratumoral injection into 4T1
tumor-bearing mice was more favorable over the corresponding
quenched probe as it exhibited a considerably enhanced signal-
to-noise ratio.
A further type of fluorescent probe whose optical properties
can be triggered upon cathepsin-catalyzed cleavage in the
absence of a quencher is compound 22 (Yuan et al., 2015).
Of note, the enhancement in fluorescence in this probe is not
mediated by electronic changes due to bond cleavage, but by a
change in solubility. Aggregation of fluorophores usually leads to
attenuation in the fluorescence intensity, a phenomenon which
is called concentration quenching (Chaudhuri, 1959). Under
certain circumstances, the contrary phenomenon of aggregation-
induced emission (AIE) can occur (Ding et al., 2013; Mei et al.,
2014). This can be observed for fluorophores based on the
tetraphenylethylene scaffold. Free in solution, the quantum yield
is low because the energy of the excited state is dissipated into
the rotation of the phenyl groups. In the aggregated state these
rotations are restricted due to intermolecular interactions and
thus the fluorescence quantum yield increases. To exploit this
principle for tumor imaging, the tetraphenylethylene scaffold has
been functionalized with a recognition sequence for cathepsin
B-catalyzed cleavage. This has been achieved by attaching
azidopropyl groups to the luminophoric core. The required
dihydroxy derivative has been accessed by a crossed McMurry
reaction from the corresponding benzophenone building blocks.
The fluorogenic core has been conjugated to a peptidic construct
consisting of the GF↓LG tetrapeptide unit, which serves as
the recognition site for cleavage by cathepsin B (Rejmanova
et al., 1983). The N-terminal propargylglycine allows conjugation
to the azido-functionalized fluorophore by azide-alkine 3+2
cycloaddition. Via a C-terminal linker consisting of three
aspartic residues, which confer hydrophilicity to the probe, the
cyclopentapeptide c[fKRGD] is attached via its lysine side chain.
The latter unit is intended to target the αvβ3 integrin type
receptor, which is overexpressed in several tumor cells. Thus,
compound 22 represents a dual-targeted probe similar to the
folate conjugate 18 with the cyclic RGD unit corresponding
functionally to the folate moiety. The azido-functionalized
tetraphenylethylene derivative has been characterized regarding
their media-dependent luminescence and has been found to
be almost non-fluorescent dissolved in DMSO. Upon addition
of water, the fluorescence steadily increased and at a mole
fraction of 99% water the emission intensity was 105-fold higher
than in pure DMSO. The emission spectra are characterized
by maxima at 615 nm upon excitation at 365 nm. Notably, the
emission is independent of pH in the range of 7.4 to 5.0. Due
to its hydrophilicity, probe 22 is virtually non-fluorescent in
aqueous solution in the uncleaved state. Incubation of 22 (5µM)
with cathepsin B (1µg/mL) for 60min at a pH 5.0 and 37◦C
resulted in a 35-fold increase of fluorescence. The performance
constant of 22 toward cathepsin B has been determined to
be 142 M−1s−1. RP-HPLC analysis of cathepsin B-incubated
22 indicated elution at considerably higher retention times
and thus higher hydrophobicity than in the uncleaved state.
Hydrophobic clustering upon cleavage has been confirmed by
laser light scattering and atomic force microscopy investigations.
Activation of 22 can also be achieved by lysates derived from
the human mammary carcinoma cell lines MDA-MB-231 and
MCF-7, while the increase in fluorescence with lysates of human
embryonic kidney cells 293T and tumor cells that have been
preincubated with CA074Me (9b) is considerably less strong.
Fluorescence microscopic analysis indicated that cell uptake of
22 occurs to a substantial extent only in the αvβ3 positive
MDA-MB-231 cells. Cell-associated red fluorescence in these
cells declines upon preincubation with either or both free RGD
cyclopentapeptide and compound 9b, which has been confirmed
quantitatively by FACS analysis. Fluorescent molecules can
potentially act as photosensitizers for photodynamic therapy
because transition from the excited triplet state to the ground
state can be coupled to conversion of triplet oxygen into highly
reactive singlet oxygen. To evaluate the probe’s potential toward
this application, Yuan et al. monitored the release of reactive
oxygen species in the presence of 22 and cathepsin B with 1,3-
diphenylisobenzofuran (DBPF) as indicator. The cleaved probe
exhibited a photosensitizing activity which was abolished in the
presence of ascorbic acid. Investigation of the light-mediated
cytotoxicity of 22 toward MDA-MB-231 cells has revealed that
under irradiation a concentration of 5µM can reduce cell
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viability by more than 50%, while in the dark the toxic effects
are minimal. The phototoxicity has been demonstrated to be
receptor-mediated, as the αvβ3 negative MCF-7 and 293T cells
are viable in the presence of 22 under irradiation at 365 nm.
Based on these in vitro results, 22 can be considered as a potential
theranostic agent, because it combines functional imaging with
targeted photodynamic ablation. To exert photodynamic effects
in vivo, excitation wavelengths above 600 nm are desirable, which
limits the applicability of 22 for therapeutic purposes.
The development of imaging probes is not restricted to
compounds of low molecular weight and a few polymeric and
particulate probes for the in vivo detection of cathepsin B have
been described. Among the first macromolecular probes for this
purpose is a poly-L-lysine-based polymer, whose amino groups
were partially functionalized with Cy5.5. The spatial proximity
of the fluorophores led to internal fluorescence quenching and
unmodified lysines served as recognition sites for cathepsin
B-catalyzed cleavage, resulting in enhanced fluorescence. In
vivo, probe activation within a mouse model of human
breast cancer correlated with the tumor-associated cathepsin
B activity (Bremer et al., 2002). In a different approach, a
nanoparticle consisting of O6-hydroxyethylchitosane (chitosane
= deacetylchitin) has been functionalized with the heptapeptidic
cathepsin B recognition sequence GRR↓GKGG to a substitution
degree of 21 peptide chains per 1 molecule of chitosane-
based nanoparticle (Figure 9, compound 23) (Ryu et al., 2011).
The particles exhibited a molecular weight of 345 kDa and a
spherical shape with a diameter of 280 nm. The hexapeptide
was equipped with Cy5.5 at the N-terminus and BHQ-3 at
the side chain of Lys as fluorescence emitter and quencher,
respectively. Exposure of the nanoprobe to 1.5 nM of cathepsin
B resulted in an approximately 15-fold increase in fluorescence,
while no significant dequenching was observed with cathepsin
L, the aspartic protease cathepsin D or cathepsin B in the
presence of Z-Phe-Lys-FMK (1b) as inhibitor. The uptake
of the cathepsin B-responsive nanoparticle in SCC7 murine
squamous cell carcinoma was accompanied by increasing red
fluorescence, which colocalized with the green fluorescence for
immunohistochemical detection of cellular cathepsin B. The
cell-associated Cy5.5 fluorescence signal could be blocked by
treatment with 1b and the particulate probe resulted in stronger
NIR fluorescence than the isolated, soluble quenched peptide.
The in vivo evaluation of the nanoprobe 23 was performed in
mice bearing SCC7 tumors. The tumor-associated fluorescence
increased up to 6 h p.i. Regarding the influence of inhibitor
treatment and the comparison with the non-particulate probe the
results obtained in cellulo could be confirmed. The fluorescence
in non-target organs was more than twice as low as in the tumor.
In a further study, this probe was re-evaluated in mice bearing
tumors derived from HT29 human colorectal carcinoma cells
(Ryu et al., 2014). Intravenous injection of the nanoprobe into
these animals resulted in NIR fluorescence signals that were
17-fold higher than in the control animal where the tumor-
associated cathepsin B activity has been blocked by intratumoral
injection of 1b. Furthermore, the probe’s capability to image
the metastasis-associated cathepsin B activity in three different
mouse models of metastatic tumors was evaluated. The first
model concerned metastasis to the liver of 4T1-luc2 cells
injected into spleen. Liver metastases were detectable 10–14
days after tumor cell injection into the spleen by luciferase-
based bioluminescence imaging. Systemic administration of
the cathepsin B-responsive nanoparticle resulted in a NIR
fluorescence that matched the bioluminescence signal, while
only minimal fluorescence was detectable upon injecting the
probe into normal mice. The increased expression of cathepsin
B in liver metastases has been confirmed by Western blot
analysis. Similar results were obtained when murine red-
fluorescent-protein-expressing RFP-B16F10 melanoma cells or
highly malignant HT1080 cells were injected into the tail vein
and into the peritoneum, respectively. The former experiment
models the process of metastasis to the lung and the latter that of
peritoneal metastasis. The uptake of the cathepsin B-responsive
nanoprobe has been investigated in all these four tumor cell
lines by fluorescence microscopy. A strong cell-associated Cy5.5-
derived fluorescence was observable for the tumor cells, whereas
only faint signals were detectable for the cathepsin B-negative
NIH3T3 mouse embryo fibroblasts.
The design of cathepsin-sensitive nanoprobes not only offers
the opportunity of functional tumor imaging, but also the
selective delivery of chemotherapeutic agents into the tumor. The
creation of such a cathepsin-responsive particulate nanocarrier
was the motivation behind the work of Li et al. (2014). The
nanoparticle has been composed of a quantum dot (QD) core
structure based on cadmium telluride (CdTe). Compared to
classical organic fluorophores, QD’s exhibit broad absorption
and narrow emission spectra and enhanced brightness. Their
emission maxima can be tuned between 450 and 850 nm
by changing their size (Lakowicz, 2010; Barreto et al., 2011;
Wegner and Hildebrandt, 2015). The CdTe core was coated
with mesoporous SiO2. The mesoporous silica shell bears the
potential to adopt doxorubicin, a member of the anthracycline
class of DNA-targeting antitumor antibiotics, which is intended
to be delivered to the site of action in the cell nucleus with the
help of the nanocarrier. A maleimido group was conjugated to
the amino-functionalized surface of the silica shell via a 4,7-
dioxanonanoyl linker. The maleimido group served as an adapter
for the attachment of the 20 mer peptide H-CRRRQRRKKR-
PGFK↓-EEEEEE-OH via Michael addition of its N-terminal
cysteine residue (Figure 9, compound 24). The peptide chain
consists of an N-terminal cell-penetrating sequence which is
attenuated by the C-terminal polyanionic hexaglutamate chain.
Both elements are linked by the PGFK tetrapeptide which serves
as recognition site for cathepsin B-mediated cleavage. Scanning
and transmission electron microscopy indicated a confined size
distribution of the nanoparticles with an overall diameter of
40 nm, which was considered as a suitable size to achieve
effective cell penetration and targeted nuclear delivery. The
fluorescence of the particle due to the CdTe QD core is around
560 nm. The empty nanocarrier was evaluated using confocal
laser scanning microscopy toward human A549 adenocarcinoma
cells as cathepsin B positive cell line and NIH3T3 mouse embryo
fibroblasts as negative control. After 24 h of incubation, the
yellow QD fluorescence is mainly located inside the nucleus of
A549 cells, whereas in the cathepsin B negative NIH3T3 cells the
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FIGURE 9 | Polymeric/particulate fluorescent probes for cathepsin B. Due to its complexity and size, probe 24 is only schematically represented.
fluorescence is restricted to the cytoplasm. A similar distribution
of the nanoparticle can be observed in A549 in the presence of
the broad-spectrum cysteine cathepsin inhibitor antipain (12).
These results suggest a cathepsin B-mediated direction to the
cell nucleus for the nanoparticle. Loading of doxorubicin to the
nanocarrier can be achieved to a degree of 10.7%. Release of
doxorubicin from the nanocontainer is clearly accelerated at pH
5.5 in the presence of cathepsin B.
In accordance with the above results, after 24 h of incubation
with the loaded nanocarrier, red doxorubicin fluorescence in the
nucleus was only detectable in the A549 cells and not in the
NIH3T3 cells. In contrast, upon incubation with free doxorubicin
over the same time, red fluorescence was detectable in the nuclei
of both cell lines. Exposure of the tumor cell lines A549 and
A2780 to the doxorubicin-loaded particles at a concentration
of 10µg/mL led to compromised cell viabilities that were
lower than under equal concentrations of free doxorubicin.
This difference was especially noticeable for the doxorubicin-
resistant cell line A2780/Adr, where free doxorubicin elicits only
minimal effects, due to the mechanisms of multidrug resistance,
which actively transport chemotherapeutic agents out of the
tumor cell. For comparison, the empty nanocarrier displays only
minimal toxicity toward the investigated cell lines. These results
allow concluding that the enzyme-responsive nanocarrier has the
potential to considerably improve chemotherapy by selectively
delivering cytostatic drugs to the nucleus of cathepsin B positive
tumor cells and circumventing mechanisms of drug resistance.
Radiotracers
Compared to fluorescence-based methods, detection on the
basis of ionizing radiation emitted by nuclides that undergo
radioactive transformations is generally more sensitive.
Therefore, probes consisting of molecules labeled with
radionuclides, so called radiotracers, offer the possibility of
sensitive detection both for in vitro investigations and imaging
applications with very often minimal structural changes
compared to the unlabeled ligand. The scope of application for
radiotracers is determined by the nuclear-physical properties
of the radionuclides they are labeled with. Table 1 summarizes
the properties of radionuclides that have been employed for the
design of cysteine cathepsin-targeting radiotracers. Long-lived
radionuclides that exhibit low particle energy such as tritium and
carbon-14 offer the possibility of sensitive detection of enzyme
inhibitor complexes and provide the possibility to study the
biodistribution and biotransformation of cathepsin inhibitors
of potential therapeutic interest by radio-HPLC and ex vivo
autoradiography (Solon, 2012; Uhl et al., 2015). Their use for
imaging is not possible because the β− particles are difficult to
measure outside the organism. For this purpose, short-lived
radionuclides that undergo transformations accompanied by
the emission of γ-ray photons can be applied for single-photon
computed tomography (SPECT). The other modality of nuclear
imaging, positron emission tomography (PET), depends on
the use of tracers labeled with neutron-deficient radionuclides
that stabilize by the transformation of a proton into a neutron
under the emission of a positron. Because positrons are the
anti-particles to electrons, the emitted positron will undergo
annihilation upon collision with an electron under the emission
of two γ-ray photons of 511 keV in the angle of nearly 180◦ to
each other. This physical phenomenon allows the construction
of images and time-activity curves by coincidence detection of
the two photons using a circular array of scintillation detectors
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TABLE 1 | Properties of radionuclides used in cysteine cathepsin-targeting radiotracers.
Radio-nuclide T1/2 Decay mode Particle/radiation energy Production Modality Labeling
(abundance)* (Emean in keV)** (nuclear reaction) chemistry
3H 12.32 a β− 5.7 Reactor (6Li(n, α)) In vitro Covalent
11C 20.4min β+ (99.8%) 386 Cyclotron (14N(p, α)) PET Covalent, mostly electrophilic
14C 5730 a β− 49.5 Reactor (14N(n, p)) In vitro Covalent
18F 109.8min β+ (97%) 249 Cyclotron (mostly 18O(p, n)) PET Covalent, mostly nucleophilic
64Cu 12.7 h β+ (18%) 278 Cyclotron (64Zn(p, n)) PET Coordinative
125 I 59.4 d EC 26.4 Reactor (124Xe(n, γ)125Xe(EC)) In vitro (SPECT) Covalent, mostly electrophilic
177Lu 6.7 d β−, γ 133 (β−), 208 (γ) Reactor (mostly 176Lu(n, γ)) SPECT, therapy Coordinative
*For clarity, only those nuclear transformations that are relevant for the imaging process are shown.
**Data have been retrieved from the Brookhaven National Nuclear Data Center6.
(James and Gambhir, 2012). This makes PET to a unique
method for quantitative tracing compounds in living organisms
(Bergmann and Pietzsch, 2005). Of note, far reaching progress
in clinical PET technology has also led to the design and
development of dedicated small animal PET systems that now
are abundantly prevalent in biomedical and pharmaceutical
research. This enables researchers to perform preclinical PET
studies on pharmacokinetics of novel radiotracers with high
spatial and temporal resolution, in living subjects such as in
rodent laboratory models (Brust et al., 2014).
Furthermore, the short half-lives of the most employed
PET nuclides imply that the administered amounts of labeled
substances are usually far below target saturation so that a
biochemical influence of the studied process does not occur
(McCarthy et al., 1994). Despite higher sensitivity of radiotracer-
based imaging, luminescence-based imaging offers the advantage
of higher spatial resolution. To take advantage of both imaging
modalities, fluorophores and radiolabels can be combined in one
molecule. Even exclusively radiolabeled compounds can be used
for OI, because the movement of high-energetic charged particles
throughmatter is accompanied by the emission of UV and visible
light known as Cˇerenkov radiation. The Cˇerenkov photons can
be detected by a CCD camera, provided that the energy of
the charged particle emitted upon radioactive transformation is
greater than 219 keV (Thorek et al., 2012). Therefore, optical
and nuclear imaging modalities are considered complementary
to each other (James and Gambhir, 2012; Chin et al., 2013;
Nordstrom et al., 2013; Seibold et al., 2014).
125I-labeled Compounds
The development of radiotracers which target cysteine
cathepsins started three decades ago with a tetrapeptide-
derived chloromethylketone-based inhibitor labeled with
iodine-125 ([125I]25a, Figure 10). Iodine-125 is one of four
biomedically relevant iodine radioisotopes (Wilbur, 1992; Mier
and Eisenhut, 2011). It stabilizes by electron capture, where a
proton combines with an electron of the inner shells, usually the
K-shell. The formed electron gap is filled under the emission
of X-ray photons. While iodine-125-based radiotracers are
6http://www.nndc.bnl.gov/.
typically employed for in vitro investigations, this radionuclide
also offers the possibility of small-animal SPECT imaging.
Radioiodination of biologically relevant compounds is very
often achieved by reacting a hydroxyphenyl moiety with an
iodine−+1 species which is generated from radioactive iodide
and a mild oxidizing agent such as iodogen. This principle has
been used to introduce iodine-125 into compounds [125I]25,
[125I]26 and [125I]28–33 (Figure 10), which are all irreversible
inhibitors that covalently target different cysteine proteases.
Compounds [125I]25a and b seem to be the first described
radiotracers to target cysteine cathepsins (Docherty et al.,
1983, 1984). They have been used to identify a protease of
31.5 kDa of the granule fraction of rat Langerhans islets as
cathepsin B by immunoprecipatation and SDS-PAGE. It is
known that peptide-derived chloromethylketones can also
interact covalently with the active site of serine proteases and
Docherty et al. (1983) demonstrated the reactivity of [125I]25a
toward trypsin. Therefore, doubts in the selectivity and the
high intrinsic reactivity of this radiotracer motivated Mason
et al. (1989b) to prepare [125I]26a as a 125I-labeled diazoketone.
The specific activity of [125I]26a was determined to be 222
MBq/µmol. Deiodo-26a has been shown to be an effective
inactivator of cathepsins L and B with selectivity over calpain,
a cytosolic Ca2+-dependent cysteine protease. Iodination to
non-radioactive 26a even improves the inhibitory properties
(Crawford et al., 1988). The radiotracer [125I]26a has been used
to identify cathepsin L and B in Kirsten-virus-transformed
NIH3T3 cells by SDS-PAGE. Electrophoretic separation of
trichloroacetic acid precipitates derived from extracts of cells
that were incubated with [125I]26a indicated the presence of
one active cathepsin B species of 33–35 kDa and two active
forms of cathepsin L of 30 and 23 kDa. For comparison,
immunoprecipitates of labeled proteins obtained by pulse-chase
incubation with [35S]methionine were separated by SDS-PAGE.
This resulted in the detection of a 39 and a 36 kDa species which
have been assigned to the intracellular precursors of cathepsin
B and L, respectively. Radiotracer [125I]26a was furthermore
applied to investigate the presence of active cathepsins B and
L in homogenates of human post mortem tissues of heart and
skeletal muscle, brain, kidney, pancreas, and spleen (Mason et al.,
1989a). Hence, [125I]26a represents an early example of an ABP.
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FIGURE 10 | Cysteine-cathepsin targeting radiotracers labeled with I-125.
Further investigations by Mason et al. led to the development
of radiotracer [125I]26b, in which the Z group of [125I]26a
has been replaced by Fmoc and a second iodo-substituent has
been attached ortho to the hydroxyl group in the tyrosine side
chain (Xing et al., 1998). Notably, the non-radioactive reference
compound 26b showed an inhibitory potential toward cathepsin
B that was 15-fold higher than that of its deiodinated counterpart
and more than twice as strong compared to the corresponding
monoiodinated derivative. Considering inhibition of cathepsin
L, the influence of iodination was inverse compared to cathepsin
B, while inhibition of cathepsin L by 26b was still faster than
that of cathepsin B. 26b was devoid of inhibitory potency toward
cathepsin S. Radioiodination of deiodo-26b in the presence
of non-radioactive sodium iodide resulted in the formation of
[125I]26b. Thus, [125I]26b represents a carrier-added radiotracer
in contrast to non-carrier-added [125I]26a. This is reflected by
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the specific activity of [125I]25b, which is with 8.3MBq/µmol
considerably lower than that of [125I]26a. Incubation of [125I]26b
with a panel of human breast tumor cells and subsequent cell
lysis and electrophoretic protein separation by SDS-PAGE
showed that these cells contain up to four different molecular
species of cathepsin L and two different forms of cathepsin B.
The knowledge of the radiotracer’s specific activity enabled the
calculation of quantitative amounts of the different cathepsin
B and L species in these cells in pmol/mg of cellular protein.
Interestingly, these studies have revealed that higher levels of
active cathepsins B and L are expressed in invasive breast tumor
cells (MDA-MB-231, MDA-MB-435S and HS-578T), compared
with those that are not invasive (MCF7 and SK-BR-3).
A diazoketone warhead is also contained in the activity-based
probe [125I]27 (Falgueyret et al., 2004). Its labeling with iodine-
125 has been done in a manner that is independent of the
presence of hydroxyphenyl groups, which will be explained more
in detail below. Non-radioactive 27 has been characterized as a
potent inactivator of the cathepsins B, K, L and S. Its potency is
ranked in the order K>L≈S>B. This inhibition profile allowed
to use radiolabeled [125I]27 for the identification of the pairs of
cathepsins B/L and B/K in human HepG2 hepatoma cells and
rabbit HIG82 synoviocytes, respectively, and cathepsin S in the
Ramos B lymphoma (human Burkitt’s lymphoma) cell line, which
has been done by incubating the probe with the corresponding
cell lysates and subsequent electrophoretic separation by one
and two-dimensional SDS-PAGE. The 125I-labeled enzyme-
inhibitor complexes were detected autoradiographically and the
results have been verified by Western blotting using specific
antibodies for the individual cathepsins. [125I]27 was also used
to determine the in cellulo efficiency of cathepsin inhibitors in
so called whole-cell enzyme occupancy assays. In such assays,
cells are preincubated with the inhibitor of interest at varying
concentrations for a defined time followed by incubation with
the radiolabeled probe. Subsequent cell lysis and separation as
outlined above followed by measuring the radiographic density
of the electrophoretic spots and data analysis provide the cellular
IC50-values for distinct cathepsins. As the authors noted, to
obtain meaningful values for reversible inhibitors, the assay has
to be performed under conditions in which the irreversibly
binding probe does not displace the inhibitor from the enzyme.
Therefore, careful optimization of the incubation time with the
radiolabeled probe is required. By applying the methodology
outlined above, radiotracer [125I]27 has been also used to identify
cathepsin S in blood in vitro and to determine the occupancy
of cathepsin S by a dipeptide-derived nitrile closely related to
odanacatib in blood of rhesus monkeys ex vivo (Veilleux et al.,
2011).
The development of 125I-labeled radiotracers for cysteine
cathepsins based on irreversible inhibitors different from
diazoketones was pursued by Bogyo et al. (2000). The lead
structures for tracer design were the epoxysuccinyl derivatives
JPM-565 (7a), CA074 (9a) and the dipeptide-derived phenyl
vinyl sulfone LHVS (5). These compounds have been selected
because 7a offers the opportunity of promiscuous targeting of
several cysteine cathepsins such as L, B, and S, whereas 9a
and 5 are selective inactivators of cathepsin B and cathepsin
S, respectively. To allow the facile introduction of radioiodine,
the leads had to be equipped with hydroxyphenyl moieties.
For the vinyl sulfone 5, this was achieved by attachment of
a hydroxyl group to the phenyl residue para to the sulfonyl
group resulting in deiodo-28. In the case of CA074 (9a) the N-
bound propyl chain was replaced by a 2-(4-hydroxyphenyl)ethyl
residue. This structural change slightly attenuated the inhibitory
activity but the selectivity for cathepsin B was retained. The
non-radioactive tracer compound 30a has not been evaluated
kinetically but iodination has been judged to be tolerable to the
enzyme-inhibitor interaction on the basis of molecular docking.
The in cellulo evaluation of the radiotracers [125I]28, [125I]29a
and [125I]30a has been performed in the dendritic cell line DC2.4,
the human pro-monocyte cell line U937 and cytotrophoblasts
derived from human placenta in a similar fashion as in the works
described above. Only [125I]30a was able to visualize specifically
cathepsin B on the radioelectropherograms. The specificity of
this radiotracer toward cathepsin B was further confirmed by
comparing lysates of splenocytes from wildtype mice or mice
in which the cathepsin B, S, or L gene had been deleted
using radio-SDS-PAGE. The radiotracers [125I]29a and [125I]30a
were used to analyze the levels of active cysteine cathepsins
in homogenates of patient-derived neoplastic tissues obtained
from normal, primary andmetastatic tumors. The corresponding
radioelectropherograms indicated an increase in cathepsin B
labeling in metastatic tissue relative to primary tumors and
normal tissue, even though the extent of upregulation differed
among the individuals. In contrast, the intensity of the cathepsin
S band was lower in the tumor samples. Invasion of cells to other
tissues is part of normal developmental processes of organisms.
An example is the migration of cytotrophoblasts to the uterus
during the development of the human placenta. Differently to
tumor metastasis, these processes are strictly regulated. The
differentiation of cytotrophoblasts toward the invasive phenotype
was stimulated by the presence of ECM-mimicking matrigel and
the active cysteine cathepsins in the lysates were detected by
[125I]29a and [125I]30a and radio-SDS-PAGE. The presence of
cathepsin S and B increased over the time of matrigel exposure.
This nicely illustrates how radiotracers that covalently interact
with enzymes can be used to shed light on their role in biological
processes with the help of proteomics-related approaches.
The probes [125I]31 and [125I]32 combine the 125I-radiolabel
with a biotinyl tag as affinity label to enable detection of
the enzyme-inhibitor complexes by two independent modalities
(Greenbaum et al., 2000). Both radiotracers are derived from
E64 (6), whose agmatine moiety has been replaced by a tyrosyl
lysine amide to obtain deiodo-31. Inserting an aminohexanoic
spacer between the tyrosine and lysine residues resulted in
deiodo-32. Similar as for [125I]30, which retained the selectivity
of CA074 (9a) toward cathepsin B, [125I]31 and [125I]32
exhibited pan-reactivity against lysosomal cysteine cathepsins
similar to their parent compound E64 (6). The probes have
been evaluated similar as the other 125I-labeled epoxysuccinyl
derivatives discussed above. Their labeling profiles in radio-
SDS-PAGE were similar to that of [125I]29a. In addition, the
labeling profiles of deiodo-31 and deiodo-32 were determined
by Western blotting using an avidin-horseradish peroxidase
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conjugate. In the range of 20–40 kDa the band patterns for
both detection modes are consistent, whereas streptavidin-based
detection exhibited additional bands in the range above 40 kDa.
This finding has been mainly attributed to the presence of
endogenously biotinylated proteins in the cell lysates. [125I]32 has
been used to perform facile selectivity profiling of inhibitors in
the presence of cell lysates. A library of derivatives of deiodo-
32 has been synthesized where the leucine residue has been
replaced by all other proteinogenic amino acids except for
cysteine and methionine, which was replaced by norleucine.
Their selectivity profiles have been evaluated by addition of each
inhibitor to DC2.4 lysates at a concentration of 50µM prior to
addition of [125I]32 and subsequent simultaneous electrophoretic
separation. Furthermore, deiodo-32 has been used for the
identification of cysteine cathepsins in rat kidney tissue
homogenates. Fractionation by anion exchange chromatography
guided by SDS-PAGE was followed by concentration of the
pooled fractions of interest using an avidin column. The
concentrated fractions were subjected to two-dimensional SDS-
PAGE and the excised and trypsin-digested spots were analyzed
by mass spectrometry. The results unambiguously identified the
cathepsins B, H and L and thus confirmed these enzymes to be
the major cysteine proteases in kidney tissue. The application
of [125I]32 and deiodo-32 for radioactivity measurements and
mass spectrometry as independent detection modes demonstrate
the versatility of these dual-label probes. [125I]32 has further
been used in defining biological functions of papain-like cysteine
proteases, such as the role of cathepsin L as alternative
prohormone convertase to liberate the peptidic neurotransmitter
enkephalin in the brain (Yasothornsrikul et al., 2003) and
elucidation of the function of parasitic cysteine proteases in
invasion of host tissues (Greenbaum et al., 2002; Dvorak et al.,
2009).
To create such dual-label probes which enable to address
a broad range of cysteine proteases such as various clan CD
enzymes (caspases, legumain and the bacterial gingipains), the
acyloxymethylketone-based probes [125I]33a-f were developed
(Kato et al., 2005). Upon varying the residue in P1, the different
proteases could be visualized by radio-SDS-PAGE. When leucine
was introduced as P1 amino acid, the CA enzyme cathepsin L was
also efficiently labeled in the radioelectropherograms.
Peptide-derived acyloxymethylketones were also the basis for
the design of the cathepsin B-targeting radiotracers [125I]34a
and b (Figure 10) (Edem et al., 2014). The dipeptide portion
consists of the Phe-Lys scaffold and the 125I-carrying groups are
attached via the lysine side chain. Regarding the introduction of
radioiodine a more sophisticated approach has been chosen than
for the radiotracers discussed so far. The electrophilic iodination
is done on an aromatic group containing an electrofuge differing
from a proton which implicates the advantage of independence
from a neighboring +M substituent. Such electrofuges are
typically metallyl groups of group 13 and 14 elements, with
trialkylstannyls being the most commonly used ones (Kabalka
and Varma, 1989). Generally, groups of this type, which facilitate
the introduction of the radionuclide, are called prosthetic
groups. In the case of radioiodination the use of prosthetic
groups can have direct implications on pharmacokinetics. Iodine
radioisotopes attached at the 3-position of 4-hydroxyphenyl
moieties can be removed by the action of deiodinases, enzymes
that participate in the metabolism of thyroid hormones. Because
enzymatic aromatic deiodination is impeded in the absence
of the hydroxy group, moieties that result in labeled meta-
and para-iodobenzoyl groups are suitable for the metabolically
stable introduction of radioiodine (Mier and Nissen, 2010).
However, the introduction of such prosthetic groups into
protein-binding ligands can potentially impede their binding
affinity due to their increased steric demand. This was observed
in the study of Edem et al. when the 4-iodobenzoyl group
was directly attached to the ε-amino group of the lysine
side chain as the second-order rate constants kinact/KI for
inactivation dropped by 50-fold compared to the unmodified
parent compound. When the iodo-substituent was introduced
in the meta-position, the loss in inhibitory activity was even
stronger. The insertion of an aminohexanoic linker between Nε
and the iodobenzoyl group did not result in restored inhibitory
potency, but when the spacer length was extended from a
pentamethylene to a three-unit poly(ethylene glycol) (PEG)
chain the inactivation rates approached the range of the parent
compound, again with meta-iodo substitution resulting in less
efficient inhibition than para. Both 34a and bwere synthesized in
their 125I-labeled versions. For this purpose, their corresponding
tris(tridecafluorooctyl)arylstannanes were prepared and reacted
with sodium [125I]iodide in the presence of iodogen at room
temperature under slightly acidic conditions. The tin-bound
fluoroalkyl groups allow separating the radiotracer products
from the excess of precursor by simple fluorous solid-phase
extraction, to provide [125I]34a and b in high radiochemical
purities and specific activities of >23 GBq/µmol. The ability of
both radiotracers to target cathepsin B has been demonstrated
by radio-SDS-PAGE analysis of the 125I-labeled enzyme-inhibitor
complex. Due to the prolonged incubation time of 1 h, also the
less potent inhibitor [125I]34awas capable of cathepsin B labeling
to a similar extent as [125I]34b. The labeled bands did not appear
when the radiotracers were incubated with cathepsin B in the
presence of CA074 (9a). To obtain information regarding their
tumor-targeting ability, [125I]34a and b were investigated in ex
vivo biodistribution studies in immunodeficient mice bearing
tumor xenografts derived from the human MDA-MB-231 breast
cancer cell line. The distribution of the 125I activity across the
different organs including the tumor was determined at time
points 0.5, 5, and 23 h p.i. An increased uptake of activity in the
thyroid after 5 h p.i. indicates themetabolic release of [125I]iodide
from both radiotracers. The tumor/muscle ratio for [125I]34b
steadily increased over time and reached a value of 7.3 after
23 h p.i., which is significantly higher than that for [125I]34a.
This result is in agreement with the higher inhibitory potency
of [125I]34b. The liver uptake of [125I]34b was approximately
5-fold reduced compared to that of [125I]34a, which has been
attributed to the hydrophilicity that is conferred by the three-
unit PEG linker. Therefore, the study by Edem et al. (2014)
provides for the first time data on the in vivo behavior of a 125I-
labeled cathepsin inhibitor, whereas the characterizations of the
other radiotracers discussed so far were focused on their in vitro
application.
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Radiotracers Based on Fluorine-18, Radiocarbon
Isotopes and Tritium
Besides iodine-125, radiopharmaceutically relevant radioisotopes
can be found for each element within the halogen group of
the periodic table (Adam and Wilbur, 2005; Wuest, 2005; Engle
et al., 2011). In regard to PET, fluorine-18 is certainly the
most important one as it has favorable properties such as high
content of positron emission (97%) and intermediate half-life
of 109.8min (Table 1). Its rather long half-life—compared to
other non-metallic PET nuclides—enables multi-step syntheses
within one to three half-lives. Because furthermore fluorine
forms very stable covalent bonds with carbon, this radiohalogen
is unparalleled in being used for the development of small
molecule-based PET tracers (Miller et al., 2008; Cole et al.,
2014).
Compound [18F]35 (Figure 11) represents the first 18F-
labeled radiotracer targeted against cysteine cathepsins (Löser
et al., 2013). This molecular probe is based on an inhibitor
of the azadipeptide nitrile chemotype. Azadipeptide nitriles
have been characterized as highly potent toward papain-like
cysteine proteases and stable against the degradation by other
proteases (Löser et al., 2008; Frizler et al., 2011; Yang et al.,
2012). To enable the convenient introduction of fluorine-
18, the tyrosine residue in P2 position was etherified with
a fluoroethyl chain. The non-radioactive reference compound
35 exhibited high binding affinities toward the oncologically
relevant cathepsins B, L, S, and K. The Ki-value for cathepsin
B was 2.4 nM, whereas those toward cathepsin L, S, and
K were in the subnanomolar range. The process of 18F-
labeling to obtain the corresponding radiotracer [18F]35 was
established as a two-step, one-pot radiosynthesis. In this
procedure [18F]fluoride was converted with ethylene glycol-
1,2-dinosylate to 2-[18F]fluorethyl nosylate which was reacted
without isolation with the corresponding phenolic precursor.
This approach resulted in higher radiochemical yields for
[18F]35 than the use of 2-[18F]fluoroethyl tosylate, which is the
commonly employed agent for 18F-fluoroethylations (Zhang and
Suzuki, 2007). The developed procedure was also superior to the
direct conversion of corresponding benzenesulfonate precursors
with [18F]fluoride. The well-established 18F-labeling process
allowed the extensive radiopharmacological characterization
of [18F]35 in immunodeficient mice bearing xenografted
tumors derived from the human lung carcinoma cell line
NCI-H292. Immunohistochemical investigations confirmed the
presence of the targeted cathepsins in the neoplastic tissue.
Radiotracer [18F]35 was studied for its ex vivo biodistribution
and pharmacokinetics and stability in vivo in rats and mice.
Slow blood clearance of the 18F-activity results from conjugate
formation between [18F]35 and glutathione and retention of the
formed metabolite in the erythrocytes, which has been confirmed
by in vitro experiments. Despite rapid biotransformation,
approximately 35% of the original radiotracer was still detectable
in the blood activity fraction at 60min p.i., which suggests that it
should be available to the tumor-associated cysteine cathepsins.
Accordingly, the tumor/muscle and tumor/blood ratios in the
NCI-H292 carryingmice as determined by dynamic PET imaging
were slowly increasing with tumor/muscle ratios reaching values
significantly greater than three at 120min p.i. This can be
considered as indicative of a specific tumor accumulation (Löser
et al., 2013). Therefore, despite unfavorable pharmacokinetic
behavior due to inherent thiol reactivity, azadipeptide nitriles
seem to be capable of tumor targeting.
Cathepsin-targeting radiotracers based on cyano group-
containing inhibitors have been also developed by Rodnick
et al. (2014). In difference, the motivation of this study was
the visualization of cathepsin K activity in osseous tissue, the
inhibitor scaffold was non-peptidic and the chosen radiolabel
was the positron emitter carbon-11 instead of fluorine-18
(Table 1). The choice of the radiolabel was influenced by the
fact that 18F-labeled tracers can potentially undergo in vivo
defluorination and the released inorganic fluoride accumulates
in the skeleton, which could have made judgements about the
specific targeting of cathepsin K in bone tissue difficult. The
selected inhibitors represent the 2-cyanopyrimidine chemotype
of cysteine cathepsin inhibitors (Teno and Masuya, 2010) with
36a and b (Figure 11) exhibiting IC50-values toward cathepsin
K of 22 and 3 pM, respectively, and a 10–1000 fold selectivity
over the cathepsins L and S (Altmann et al., 2007). Labeling
with carbon-11 for both cyanopyrimidines was performed
by 11C-methylation of the corresponding phenolic precursors
with [11C]methyl iodide generated by gas-phase reduction of
cyclotron-produced [11C]carbon dioxide (Pretze et al., 2011).
The in vivo radiopharmacological evaluation of [11C]36a and
b has been performed by dynamic PET imaging in rats. The
obtained images indicated an accumulation of 11C activity in the
distal ulna, distal femur and proximal tibia, among other regions
where bone remodeling under the involvement of cathepsin K
is occurring. The uptake of [11C]36b in these regions was 2–
3 fold higher than in muscle tissue and could be attenuated
by preinjection of non-radioactive 36b. In accordance with
this result, the uptake for [11C]36a of high specific activity
(414 GBq/µmol) was higher than that for [11C]36a of low
specific activity (10.8GBq/µmol, corresponding to co-injection
of 14µg/kg of non-radioactive 36a) (Rodnick et al., 2014). These
results support the suitability of [11C]36a and b as radiotracers to
image the activity of cathepsin K in vivo.
Imaging of cathepsin K is also in the focus of the study by
Bennacef et al. (2013) for which only preliminary results have
been published yet in abstract form. The dipeptide-derived nitrile
37 containing homocycloleucine in P2 is a potent inhibitor of
cathepsin K with an IC50 of 0.2 nM (Falgueyret et al., 2005).
[11C]37 has been synthesized by 11C-methylation of nor-37 using
[11C]methyl triflate in a specific activity of 1229 GBq/µmol. PET
imaging studies of [11C]37 in juvenile rhesus monkeys indicated
an increased uptake in actively growing bone regions (SUV’s≈2.0
for distal femur and proximal tibia vs.≈0.7 for mid-femur; SUV:
standardized uptake value). Uptake of [11C]37 was attenuated
upon pretreatment with a different inhibitor, which is selective
for cathepsin K (Bennacef et al., 2013).
Historically, carbon-11 has been used in biochemical research
many years before PET has been invented and before long-life
carbon-14 was available in larger scale, such as [11C]CO2 for early
studies on CO2 assimilation in barley plants (Ruben et al., 1939)
or to investigate its incorporation into glycogen in starved rats
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FIGURE 11 | Cysteine-cathepsin targeting radiotracers labeled with “organic radionuclides.”
(Solomon et al., 1941). Later, carbon-14 became the preferred
carbon radioisotope for in vitro investigations (Kamen, 1963,
1986), which culminated in the elucidation of the metabolic
cycle of the photosynthetic dark reaction (Calvin, 1962). Until
today, 14C-labeled compounds are of great importance to gain
insight into the ADME properties of drug molecules (Elmore,
2009; Isin et al., 2012). Such studies are integral part of
clinical drug development and the results are only occasionally
published. Considering the variety of cathepsin inhibitors that
are in clinical development, the collection of 14C-labeled tracers
related to cysteine cathepsins in Figure 11 is certainly not
complete. Contrary to radiotracers based on short-lived nuclides,
the specific activity of 14C-tracers is restricted to much lower
values. However, because long-lived radionuclides allow the
incorporation of multiple radionuclides per tracer molecule, this
limitation can be partly counterbalanced. This concept has been
realized in [14C6-phenyl]13, a 14C-labeled odanacatib (Kassahun
et al., 2011). The radiotracer has been obtained in a specific
activity of 2.9MBq/µmol and was investigated in rats, dogs, and
rhesus monkeys for its metabolite profile. The biotransformation
pathways are different in these species. In rats and dogs the
main route is hydroxylation of the sulfone methyl group followed
by spontaneous de-hydroxymethylation to the corresponding
sulfinic acid, which is either excreted or undergoes oxidation
to the sulfonic acid. In difference, the main metabolic route in
monkeys is initiated by oxidation at one of the methyl groups
in the P2 side chain, which is followed by further oxidation or
O-glucuronidation. The biotransformation of [14C6-phenyl]13
observed in monkeys was similar in humans, while the content of
excreted unmodified compound is higher in men. In accordance
with the preclinical results from animals, biliary excretion is
predominant over renal elimination and no metabolites are
retained in the circulation (Kassahun et al., 2014).
Besides ADME studies in humans, 14C-labeled compounds
are typically used in autoradiography and whole-body
biodistribution studies in small animals. In this context,
[14C]37 has been prepared in a two-step synthesis consisting
of conversion of 4-(2-(4-methylpiperazin-1-yl)thiazol-4-
yl)phenyl)lithium with [14C]CO2 followed by amide bond
formation with the corresponding deprotected dipeptide nitrile.
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The ex vivo biodistribution studies in rats have shown that the
levels of [14C]37 or its metabolites in the liver, spleen, lung and
kidney are 6–12 times higher than in the blood. These results are
interpreted to reflect the lysosomotropic character of 37, which
is conferred by the moderately basic piperazine moiety, because
the high-uptake organs are composed of cells that are rich in
lysosomes. This interpretation is in agreement with the high
volume of distribution, which has been determined to be 11 L/kg
for [14C]37 (Falgueyret et al., 2005). Lysosomotropism has been
identified as the main reason for adverse side effects observed
during the clinical development of the cathepsin K inhibitor
balicatib (Brömme and Lecaille, 2009). The dipeptide nitrile
38 is a potent and selective inhibitor of cathepsin S developed
by Boehringer Ingelheim (Lorenz et al., 2010). To obtain
information on its ADME properties, introduction of carbon-14
was achieved via Strecker reaction with sodium [14C]cyanide.
The final product [14C]38 was obtained in a specific activity of
1.8MBq/µmol. Apart from details on the radiosynthesis, no
radiopharmacological results are disclosed (Latli et al., 2012).
Another radionuclide with similar properties is tritium. In
contrast to carbon-14 it has a much shorter half-life of 12.32 years
and is therefore less problematic regarding radiation protection
issues. However, the mean energy of the electron emitted upon
disintegration of a tritium nucleus is only about 10% of that
for the 14C-borne electrons (Table 1), which means that the β−
particles emitted from tritium are almost completely shielded
by the wall of the reaction vessel. This implicates the use of
liquid scintillation counting or radioluminographic methods
for the detection of 3H activity. Other potential drawbacks of
labeling with tritium are the biological instability of the resulting
radiotracer and kinetic isotope effects, when the chemical process
to be studied involves the labeled position (Penner et al., 2012).
However, labeling of organic molecules with tritium is often
facile to achieve by methods such as exposure of compounds to
high activities of tritium gas (known as the Wilzbach method),
catalyzed 1H/3H isotope exchange or introduction by reaction
with tritiated building blocks, for example reduction of carbonyl
compounds with the tritium-based versions of complex hydrides
(Saljoughian, 2002; Voges et al., 2011). The latter strategy was
pursued by Albeck and Kliper for labeling of theN-tripeptidyl-α-
aminoalkyl epoxide 39 with 3H. Reduction of the corresponding
tripeptidyl bromomethyl ketone with sodium borotritide and
subsequent cyclization afforded epoxide [3H]39 in a specific
activity of 833MBq/mmol. Papain was incubated with equimolar
amounts of [3H]39. Separation of the labeled enzyme-inhibitor
complex by dialysis and determination of the 3H activity by
liquid scintillation counting indicated that 94% of the enzyme
associated with [3H]39. When this experiment was performed
with papain that was pretreated with the thiol-reactive reagent
DTNB or heat-denatured papain, only 9% and less than 0.5%
of [3H]39, respectively, associated with the enzyme. On the
basis of these results the authors concluded that N-peptidyl-
α-aminoalkyl epoxides interact in a 1:1 stoichiometry with the
active-site cysteine residue in papain-like cysteine proteases and
that this interaction is dependent on the catalytic competence
of the enzyme (Albeck and Kliper, 1997). This example may
serve to illustrate the expedience of radiolabeled irreversible
enzyme inhibitors to determine the stoichiometry of enzyme
inactivation.
Radiometal-based Tracers
Most of the known radionuclides are of metallic character,
which is simply due the fact that the majority of the chemical
elements are metals. Many among them are valuable for SPECT
and PET imaging (Wadas et al., 2010). A well-studied metallic
PET nuclide is copper-64 (Table 1). Compared to fluorine-18,
it offers the advantage of extended half-life and coordinative
bond formation under rather mild conditions. However, the
latter advantage implicates the drawback of modification with
spatially demanding chelators for radiotracer design, which
potentially can compromise target interaction, especially in
the case of small molecules. The 64Cu-labeled acyloxymethyl
ketones shown in Figure 12 have been the first reported PET
tracers which target cysteine cathepsins (Ren et al., 2011). The
design of compound [64Cu]40 was guided by the structure of
GB123, a fluorescent AOMK capable of cathepsin B and L
optical imaging7. Its Cy5 fluorophore has been replaced by the
macrocyclic chelator DOTA which has been connected via an
amide bond with one of its carboxymethyl groups to the Nε of
the lysine in P1 to result in the labeling precursor of [64Cu]40. To
enable equipment with a copper-64 and fluorescent label, the Z-
group was replaced by phenylalanine and the chelator relocated
from the lysine side chain to the N-terminus, which provided
the vacancy to attach a Cy5 label (precursor for [64Cu]41).
To be able to compare the activity-based probe [64Cu]41
with a substrate analog as control, its corresponding primary
amide [64Cu]42 was prepared. Labeling with copper-64 was
done by incubating the chelator-functionalized precursors with
[64Cu]CuCl2 in aqueous solution at pH 5.5 and 50◦C to obtain
the corresponding radiotracers in high radiochemical purity and
specific activities ranging between 1.1 and 17.8 GBq/µmol. The
whole-body biodistribution of the three 64Cu-labeled probes was
studied in athymic nude mice bearing subcutaneously grafted
tumors derived from the human breast cancer cell line MDA-
MB-435 and the oncogenically transformed murine C2C12/Ras
myeloblastoma line. The tumor uptake of [64Cu]40 at 24 h
p.i. was significantly higher in the C2C12/Ras tumors, which
correlates with a higher cysteine cathepsin activity in this cell
line compared to MDA-MB-435. The difference in the absolute
uptake is also reflected in differing tumor/muscle ratios. While
the radiotracer exhibited a low uptake inmost non-tumor tissues,
activity accumulation in the liver was high. This observation
has been interpreted to result from de- or transchelation of the
64Cu-copper complex, which is in accordance with results that
render DOTA suboptimal for stable complexation of Cu2+ ions
(Maheshwari et al., 2012; Cai and Anderson, 2014; Price and
Orvig, 2014; Zarschler et al., 2014). Interestingly, the uptake
of the bimodal probe [64Cu]41 in the C2C12/Ras tumors was
more than 10 times higher than that of [64Cu]40 with a
tumor/muscle ratio of 13 at 24 h p.i. This phenomenon might
be due to the amphiphilic character conferred by the Cy5
7Carbobenzoxy-capped Phe-Lys(Cy5)-acyloxymethyl ketone. http://www.ncbi.
nlm.nih.gov/pubmed/20641998.
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FIGURE 12 | Radiometal-based cysteine-cathepsin targeting radiotracers.
moiety. Also the uptake of the corresponding substrate [64Cu]42
was higher compared to [64Cu]40, but considerably lower than
that of its AOMK analog [64Cu]41. Notably, the tumor/muscle
ratio at 2 h p.i. for the substrate [64Cu]42 was in the same
range as that for the irreversible inhibitor [64Cu]40. µPET
investigations mainly confirmed the results of the biodistribution
study. PET imaging included also the investigation of the bimodal
AOMK-based probe [64Cu]41 in mice bearing murine 4T1
tumors with high cysteine cathepsin expression. Subsequent
to the end point of imaging at 24 p.i., the cathepsin activity
was investigated in tumor homogenates for all three cell lines
by SDS-PAGE. This was performed both by quantifying the
fluorescence originating from the [64Cu]41-cathepsin complexes
as well as by analyzing the residual cysteine cathepsin activity
upon addition of the fluorescence-only probe GB123 to the
tumor homogenates. For both methods the measured in-gel
fluorescence signals correlated well with the tumor/muscle
ratios determined by PET imaging. Furthermore, the tumor
uptake of [64Cu]41 was reduced by more than factor 2 upon
pretreatment with large amounts of 4, a vinyl sulfone-based
broad spectrum inhibitor of cysteine cathepsins, in mice carrying
tumors derived from the human breast cancer cell line MDA-
MB-231MFP. In conclusion, the work of Ren et al. established
very well that the intratumoral imaging signals of [64Cu]41
are associated with the cysteine cathepsin activity. Moreover,
the superiority of [64Cu]41 over [64Cu]40 demonstrates that
the conjugation of radiotracers with fluorophores may improve
their pharmacokinetic properties in addition to providing the
opportunity of bimodal imaging.
Besides in vivo diagnostics, molecules containing
radionuclides are of potential interest for targeted radiation
therapy of tumors. In particular, this applies to nuclides which
emit charged energetic particles such as β− and α particles or
Auger and conversion electrons. Preferably, their half-life should
be in the range of a few days until several weeks, and the nuclear
transformation should be accompanied by the emission of γ
photons with an energy range between 70 and 360 keV, to enable
tracking of the agents by SPECT imaging (Pouget et al., 2011;
Cutler et al., 2013). A nuclide that matches these criterions
quite well is the radiolanthanide lutetium-177 (Table 1). With a
maximum energy of 498 keV corresponding to a mean range of
670µm for the emitted β− particle it is almost ideally suited to
treat locally confined primary and metastatic lesions with limited
radiation exposure of the surrounding normal tissue (Zalutsky,
2011). Regarding its chemical properties, lutetium prefers the
oxidation state +3 and high coordination numbers with 9 being
the most encountered one. This makes DOTA a suitable chelator
for Lu3+ ions. In the resulting complexes, eight coordination sites
are occupied by the ligator atoms of DOTA and an additional is
probably provided by a water molecule. 177Lu-DOTA complexes
conjugated to bone-seeking bisphosphonates, analogs of
somatostatin and bombesin as well as a monoclonal antibody
targeting the prostate-specific membrane antigen have been
evaluated in clinical trials for the treatment of metastatic prostate
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cancer and neuroendocrine tumors (Cutler et al., 2013). Apart
from this targeted approach, conjugation of such radiometal
complexes to polymers of sufficient molecular mass and favorable
properties can be an alternative to deliver the radiation dose to
the tumor by taking advantage of the enhanced permeability
and retention (EPR) effect. This effect is mainly caused by a
fenestrated endothelium in the tumor blood vessels on the one
side and defective lymphatic drainage on the other. Therefore,
macromolecules with a molecular mass above a threshold around
20 kDa accumulate in the tumor tissue, which is also referred
to as passive targeting. A neutral charge and a molecular mass
greater than 30–50 kDa will further facilitate tumor delivery of
the polymer due to reduced renal filtration (Haag and Kratz,
2006). However, with increasing mass the chance of phagocytotic
uptake by cells of the reticuloendothelial system, especially
macrophages, rises. Because these cells reside mainly in the
spleen and the liver, toxic effects to these non-target organs
have to be taken into account for therapy with radionuclide-
carrying polymers. To tackle this problem, Ogbomo et al. (2013)
investigated the effect of conjugation of 177Lu-DOTA complexes
to N-(2-hydroxypropyl)methacrylamide-based copolymers via
cathepsin-cleavable linkers on the clearance from liver and
spleen. The structure of the polymeric constructs is schematically
depicted in Figure 12. Their synthesis has been achieved
by copolymerizing the monomeric building blocks N-(2-
hydroxypropyl)methacrylamide and the DOTA-peptide/FITC-
functionalized N-(3-aminopropyl)methacrylamides in a
molar ratio of 98:1:1, respectively. Therefore, the resulting
copolymers represent bimodal probes because one half of the
(3-aminopropyl)methacrylamide was conjugated to the chelator
and the other to fluoresceine. The peptide sequences (Gly)3-Phe
(contained in [177Lu]43a) and Pro-Met-Gly-Ile-Pro (contained
in [177Lu]43b) were chosen as linkers to mediate cleavage by
the cathepsins B and S, respectively. This selection was based
on literature reports. In both cases the tripeptide Gly-(D-Ser)2
was placed between the N-terminus and the DOTA macrocycle
as linker to facilitate clearance. A construct lacking the peptidic
linker between the DOTA moiety and the polymeric core serves
as control vehicle ([177Lu]43c). To prove the susceptibility
of the peptides to cathepsin-catalyzed hydrolysis, the isolated
demetallated DOTA-conjugated peptides derived from 43a and
b were investigated for their degradation upon incubation with
isolated cathepsin B and S, respectively. Cleavage of the peptide
contained in 43a by cathepsin B (∼0.9µM) proceeded with a
half-life of approximately 24 h while degradation of the peptide
included in 43b catalyzed by cathepsin S (∼1.0µM) was much
slower. The cleavage occurred after the second glycine residue
in 43a and between glycine and leucine in 43b, as confirmed by
mass spectrometry. Accordingly, the 177Lu-labeled polymeric
vehicles [177Lu]43a and b are cleaved by the respective cysteine
cathepsins, while all three polymers [177Lu]43a-c were stable in
serum for 72 h. To assure that tumor targeting relies exclusively
on EPR, the uptake of the demetallated copolymers was studied
by FACS analysis in the human pancreatic adenocarcinoma
cell line HPAC and macrophages. While a time-dependent
increase in cell-associated fluorescence was measureable in
macrophages for all three compounds, virtually no increase was
observed for the tumor cells within the same range. The activities
of cathepsin B and S in the HPAC cells were 70 and 10-fold
lower than in macrophages, respectively. In vivo evaluation of
177Lu-containing polymers has been performed in SCID mice
bearing xenografted tumors derived from the HPAC cell line.
The ex vivo whole-body biodistribution of [177Lu]43a-c was
investigated at 24 and 72 h p.i. At 24 h p.i. the liver uptake of
[177Lu]43a and b was lower than that for [177Lu]43c, while the
values for [177Lu]43b were in between those for [177Lu]43a
and [177Lu]43c. From 24 until 72 h p.i. the liver uptake of the
non-cleavable control [177Lu]43c increased 1.5-fold, whereas
the level of cathepsin-responsive [177Lu]43a and b remained
constant. The situation proved to be similar in the spleen
except that the level of [177Lu]43c increased even more from
24 to 72 h p.i. The tumor/spleen ratios reached after 72 h were
more favorable for the cleavable analogs [177Lu]43a and b.
Unfortunately, their absolute tumor uptakes compared to stable
[177Lu]42c were lower by factors of 3 and 2, respectively. Despite
the reasons for this result remained unclear, enhanced blood
retention and potential tumor metabolism of [177Lu]43a and
b might be possible explanations. In this context it should be
mentioned, that similar approaches exploited protease-cleavable
linkers for selective tumor delivery of therapeutic agents by
taking advantage of the tumor-associated protease activity (Gill
and Loadman, 2008).
Concluding Remarks
In the more than 80 years that have been passed since the
discovery by Willstätter and Bamann, the field of cysteine
cathepsins has seen a tremendous development in regard to the
elucidation of their structures and physiological functions in the
last two decades. Especially their roles in tumor progression and
metastasis, but also in etiology, manifestation and progression of
other diseases are more and more recognized in detail. Molecular
probes contributed to this process to a substantial extent and will
help to define the pathophysiological functions of these enzymes
even more precisely in the future. The use of radiotracers for
functional in vivo imaging of cathepsins has just been initiated
in the last years and will substantially facilitate the clinical
translation of inhibitors.
In this article we intended to provide an overview on
recently developed fluorescent and radioactive molecular probes
targeted against cysteine cathepsins. In addition, we hope that
we rendered the field of probe development palatable to the
medicinal and pharmaceutical chemist, as it combines many
exciting and diverse facets of chemistry to study intriguing
biological processes, not only in the context of cathepsins and
tumor biology.
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